Elizabeth Holmes SEC Deposition AUG 23, 2017 3 OF 4 redacted — Transcript
Full transcript
- 0:04We're back on the record at 1:17
- 0:07p.m. Ms. Holmes, did you have any
- 0:10substantive conversations with the SEC
- 0:11staff during the break?
- 0:13I did not.
- 0:14Thank you.
- 0:16Rupert Murdoch invested in the CT round
- 0:18of Theranos, correct?
- 0:20Yes.
- 0:20And he made his investment around
- 0:23January 2015?
- 0:26I had February in my mind, um but yes,
- 0:28around then.
- 0:30You were in discussions with him about
- 0:31investing in Theranos around November,
- 0:33December, and January, in that time
- 0:35frame?
- 0:36Yes.
- 0:38Did you review the binder of documents
- 0:41that Theranos sent to um Mr. Murdoch
- 0:44ahead of his his investment?
- 0:46I don't know that I reviewed it before
- 0:49he invested. I know I've seen it since
- 0:50then.
- 0:53Do you know who put the binder together?
- 0:54I don't.
- 0:57Do you know what Theranos
- 0:58who at Theranos would have had the
- 0:59responsibility to do something like that
- 1:00at the time?
- 1:01Uh again, similar to some of the other
- 1:04projects, we had different project
- 1:05managers who would compile materials
- 1:07before meetings or to follow up with
- 1:09people.
- 1:12Who would have instructed the project
- 1:13managers as to what to put into these
- 1:15binders for investors?
- 1:18I don't know that we gave binders to all
- 1:21investors. My memory is that after
- 1:24Rupert had said he wanted to invest,
- 1:26which was earlier,
- 1:28um we then said we would send him a
- 1:31a set of background materials on what we
- 1:33were trying to do.
- 1:36Okay, so you you might not have
- 1:38compiled and sent out binders to all
- 1:40investors or potential investors, but
- 1:42when you did, who would have been
- 1:45deciding what to include in these
- 1:46binders?
- 1:48Um again, I I don't think there was one
- 1:51person who was making decisions about
- 1:53this. I'm sure I had
- 1:55um discussions with the team about it.
- 1:57Sunny may have as well and
- 2:00people who were focusing on particular
- 2:02areas of the business that we want to
- 2:04share material on would have also.
- 2:07Besides you and Mr. Balwani, would there
- 2:10have been anyone else at Theranos who
- 2:11would have made decision a decision as
- 2:14to what to include or what to include in
- 2:15binders?
- 2:18Again, I I don't have memory of one of
- 2:20these specific interactions. My general
- 2:24memory is that
- 2:26whoever the subject matter
- 2:29point person was for a given area would
- 2:32aggregate materials for that area and
- 2:34that would be included.
- 2:35And who would have the final say as to
- 2:37what went into the binders or didn't go
- 2:38into the binders to investors?
- 2:41Again, I I don't know. I think it
- 2:43differed on a case-by-case basis. This
- 2:45was not a consistent practice across
- 2:48all the investors that we engaged with.
- 2:52Do you recall
- 2:54reviewing Mr. Murdoch's binder before
- 2:56you sent it to him?
- 2:57I do not.
- 2:59Do you recall sending binders to any
- 3:01other prospective investors other than
- 3:02Mr. Murdoch?
- 3:04No.
- 3:06Uh what about sort of the similar
- 3:08binders, the similar documents as what
- 3:10would be in a binder,
- 3:11just electronically, do you remember
- 3:12sending electronic documents to any
- 3:14potential investors?
- 3:15I don't have memory of it, no.
- 3:19Okay, if you would pick up exhibit 221
- 3:22again,
- 3:23which is this first document over here.
- 3:29You can turn to
- 3:32uh the page with page number ending
- 3:346306,
- 3:37which is page
- 3:3958
- 3:42of the document.
- 3:45358?
- 3:4758.
- 3:47Yep.
- 3:53Do you see there are some text messages
- 3:55here
- 3:56dated December 16th, 2014 to December
- 3:5917th, 2014. Are you on that page?
- 4:03I'm sorry, this is December 13th through
- 4:052015.
- 4:07Are you on page 58?
- 4:09Oh, I'm sorry, it's on 358.
- 4:10Okay, page 58.
- 4:12Yep.
- 4:22Okay.
- 4:27I mean, this doesn't look the same as
- 4:28mine.
- 4:32Are you sure you're on page 58?
- 4:3458 of everything.
- 4:36All right. Is this
- 4:38The date should be December 16th to
- 4:4017th, 2014.
- 4:46December 16th.
- 4:48What page number did you say it was?
- 4:506306.
- 4:526306. It's a difference.
- 4:57This could be a
- 4:59This is 68. Is it 68?
- 5:03My My copy looks like 58, but it's
- 5:05probably right. Do you see December 16th
- 5:07to 17th, 2014?
- 5:10Text messages? Okay.
- 5:12So, if you look halfway down the page,
- 5:14there's a text message from you to Mr.
- 5:17Balwani
- 5:19on December 16th, 2014 at 11:34 p.m. Do
- 5:24you see that?
- 5:25It says, "Are there any materials in the
- 5:27binders you think should be removed for
- 5:29Murdoch/News
- 5:31Corp?" Do you see that text message?
- 5:33I do.
- 5:35Are you asking Mr. Balwani for input as
- 5:37to what to include in the binder that
- 5:39you were going to provide to Mr.
- 5:40Murdoch?
- 5:43Again, I I don't remember the specific
- 5:44text, but reading it now, I I read it as
- 5:48asking for his advice on whether the
- 5:50right materials were in the Murdoch
- 5:51binder.
- 5:52So, what does this refresh your
- 5:54recollection that you would have
- 5:55reviewed Mr. Murdoch's binder before you
- 5:58sent it out?
- 5:59No, I don't have memory of doing that.
- 6:06Okay, you can put that one aside.
- 6:10Partner Fund Management, um did you
- 6:12understand that PFM was another way to
- 6:15um that Partner Fund Management was
- 6:17called? With the PFM Partner Fund
- 6:19Management are the same entity.
- 6:20I do.
- 6:21Okay.
- 6:22Uh PFM invested in the Series A round
- 6:24for Theranos, correct?
- 6:26Yes.
- 6:27How much did they invest?
- 6:30Uh I think it was 96 million.
- 6:32You were in discussions with PFM in late
- 6:342014 and January 2000 I'm sorry, late
- 6:38I'm sorry, over again. You were in
- 6:39discussions with PFM in late 2013 and
- 6:41January 2014 regarding their potential
- 6:44investment.
- 6:45Uh as I was saying,
- 6:47I met them in December of '14 and we had
- 6:49a meeting to discuss their potential
- 6:51investment in January of I'm sorry,
- 6:53December of '13 and met them
- 6:55for the first time, and then in January
- 6:57of '14 we had a meeting to discuss their
- 6:58potential investment.
- 7:00Do you remember having a series of
- 7:01meetings with them in January 2014
- 7:03before their investment?
- 7:05Um as far as I know, there's only one
- 7:07that that I was in. Um I I understand
- 7:09there were other interactions also.
- 7:11Which meeting was that?
- 7:13Um meeting which they came to
- 7:17discuss
- 7:18Theranos and our vision and whether
- 7:21get an understanding of whether
- 7:23uh it would be the right investment
- 7:24opportunity.
- 7:25Did you present any materials to PFM at
- 7:27that meeting?
- 7:29I don't recall.
- 7:31What do you recall telling them about
- 7:33Theranos?
- 7:34I I don't recall the discussion very
- 7:37well. I've seen notes uh of those
- 7:39meetings since then.
- 7:40What Whose notes have you seen?
- 7:42Um
- 7:43notes that were
- 7:46um
- 7:47taken I think by members of PFM's team.
- 7:51Which members of PFM's team?
- 7:53I don't know.
- 7:54How did you review those notes?
- 7:56Um with counsel in preparing for
- 7:59potential litigation with PFM.
- 8:01Did you review the notes anytime prior
- 8:03to reviewing them with counsel?
- 8:05No.
- 8:08Do Do you remember who from PFM you met
- 8:10with in that meeting?
- 8:11Um
- 8:12some sort of subsequent meeting at
- 8:14Theranos that you attended?
- 8:15Um I I believe he was there as well as
- 8:18members of his team
- 8:20um that were doing due diligence. I I
- 8:22don't know um what their names were by
- 8:24memory sitting here now.
- 8:27Before that meeting with uh with him, do
- 8:28you remember being introduced to him in
- 8:31December time frame?
- 8:32I do.
- 8:32Uh
- 8:33were you introduced to anyone else from
- 8:34PFM?
- 8:35I think it was in the first meeting.
- 8:37Did Do you Do you recall whether he was
- 8:38at that second meeting?
- 8:39I don't.
- 8:43Uh who was at that meeting from
- 8:45Theranos?
- 8:47Uh which meeting?
- 8:48The meeting that you were talking about
- 8:50where you met with PFM and talked about
- 8:52the vision for the company.
- 8:53In January?
- 8:54In January.
- 8:55Um
- 8:56at least myself and Sunny. I don't know
- 8:58if anyone else was in the meeting.
- 9:04I'm going to hand to you what's been
- 9:06previously marked Theranos exhibit 255.
- 9:14Is there a copy?
- 9:18Exhibit 255 purports to be
- 9:22Um and actually I also had a view
- 9:24exhibit 256 I think.
- 9:26Uh both the email and the attachment
- 9:28were marked separately as exhibits.
- 9:31Um
- 9:32exhibit 255 purports to be
- 9:34a January 17th, 2014 email from Sunny
- 9:38Balwani to subject re
- 9:40with Bates number THPFM0003870572.
- 9:48And exhibit 256
- 9:51purports to be a
- 9:53PowerPoint presentation with title
- 9:56Theranos with starting Bates number
- 9:58TS-0315637.
- 10:02Have you seen exhibit 255
- 10:07uh before?
- 10:09I don't think so.
- 10:10Have you seen exhibit 256 before?
- 10:14Um
- 10:16I don't know. It looks like an internal
- 10:19Theranos deck.
- 10:25Um
- 10:26So, if you turn back to exhibit 255,
- 10:38Is it all part of one
- 10:40doc- or maybe it's just two different
- 10:41types of paper.
- 10:43I think it might have been printed on
- 10:44two different types of paper because we
- 10:45ran out of paper.
- 10:47Okay.
- 10:47But, it is one one document.
- 10:49I understand that. Okay.
- 10:50Um
- 10:51If you turn back to exhibit 255,
- 10:54Mhm.
- 10:55um you'll see there's
- 10:59an email
- 11:01on 573, which is the second page of
- 11:04exhibit 255,
- 11:06from and to Sunny Balwani.
- 11:09And he says, "Sunny, thanks again for
- 11:11the time you spent with our team walking
- 11:12us through the Theranos story. It's
- 11:14amazing to see what you and Elizabeth
- 11:16and the rest of the Theranos team have
- 11:17accomplished over the last 10 years."
- 11:22Was the initial meeting between you, Mr.
- 11:25Balwani, and the PFM team around January
- 11:2710th, 2014?
- 11:29I think so.
- 11:30Would he have been referring to that
- 11:31meeting with you and Mr. Balwani?
- 11:35I don't know. I mean, I could
- 11:37infer that from looking at this email
- 11:39right now, but I don't know.
- 11:45Okay, and if you turn um
- 11:48to exhibit 256, then you'll see that
- 11:52and actually, if looking back at exhibit
- 11:54255, you'll see that Mr. Balwani is
- 11:56sending a uh presentation to
- 11:59Um he says, "Attached, please find a PDF
- 12:01which is a very confidential slide deck
- 12:03of discussions we had."
- 12:06You see that?
- 12:07Mhm.
- 12:07And then he is attaching a very long
- 12:09presentation, which is at exhibit 256.
- 12:14Do you remember presenting this
- 12:15presentation to and the rest of the PFM
- 12:19team at that January 2014 meeting?
- 12:22I don't think we presented it.
- 12:24And what do you What do you recall
- 12:26presenting?
- 12:28Uh my memory is that we did not present
- 12:29slides. We had a discussion.
- 12:33So, your testimony is that you remember
- 12:34not presenting slides, but having a
- 12:36discussion?
- 12:37Yes, and I think there may have been one
- 12:39slide that was pulled up, which resulted
- 12:42in a request for the deck, but I don't
- 12:43think we
- 12:44did a presentation to a slide deck. I
- 12:46think we We may have used a slide in
- 12:48support of a discussion point.
- 12:50Which slide uh do you recall using
- 12:53during that meeting?
- 12:53I I don't know. I don't remember it.
- 12:56So, you recall a slide um being the
- 12:59impetus for PFM requesting the slide
- 13:02deck, but you don't remember what that
- 13:03slide was.
- 13:04Yes.
- 13:07So, looking through the presentation
- 13:15you said that this looks like some kind
- 13:17of internal uh Theranos presentation. Do
- 13:20you recall that this testimony?
- 13:23Um
- 13:24who would have prepared this slide deck?
- 13:28I I don't think it was one person. I
- 13:29think it was an aggregation of content
- 13:32from different areas of the company that
- 13:34we just kept on adding to over time.
- 13:37Were you involved in preparing any part
- 13:38of this presentation?
- 13:41I I don't know. I I haven't gone through
- 13:43the whole thing. I'm just flipping
- 13:45through it. It looks like it's
- 13:47it's a lot of content about different
- 13:49parts of our company.
- 13:52Was Mr. Balwani involved in preparing
- 13:55parts of this presentation?
- 13:56I don't know.
- 14:01Uh just generally during that January
- 14:032014 meeting with PFM, were there parts
- 14:06that you
- 14:07discussed with PFM versus parts that uh
- 14:11Mr. Balwani discussed with them?
- 14:13And what are what are some of the topics
- 14:16uh you recall discussing with PFM versus
- 14:18what Mr. Balwani discussed?
- 14:20So, I I don't have recollection of
- 14:22specific conversations in the meeting. I
- 14:24know in general in these initial
- 14:26meetings with investors, I would talk
- 14:28about our vision and what we were trying
- 14:29to do as a company.
- 14:32What did you recall Mr. Balwani talking
- 14:34about?
- 14:35Again, I I don't have specific
- 14:36recollection of of what we said in the
- 14:38meeting.
- 14:40As a as a general matter, would he have
- 14:41a role in in certain topics more
- 14:44prominently?
- 14:45Yes, I'm on the operations of the
- 14:47business and on the models or
- 14:51projections that we were putting
- 14:52together.
- 14:54Okay, so I just want to draw your
- 14:55attention to a couple of the slides in
- 14:57this presentation. So, if you turn to
- 14:59644.
- 15:20This slide is titled media. Do you see
- 15:23that? And the third bullet point was was
- 15:25I correct in that?
- 15:26Yes.
- 15:27And the third bullet point down it says
- 15:29not disclosing device, work with
- 15:32hospitals and or the DOD or future
- 15:35innovations or expansion plans.
- 15:37Do you recall ever
- 15:39um
- 15:40putting together slides or documents
- 15:42with that statement?
- 15:44No.
- 15:45Do you know do you have any
- 15:46understanding as to what this is talking
- 15:47about?
- 15:49Sitting here now, I read it to mean that
- 15:52we were not disclosing to the media uh
- 15:56essentially the the plan for the mini
- 15:58lab uh
- 16:00work with hospitals or other future
- 16:02innovations or expansion plans.
- 16:04Did you have that same understanding in
- 16:06January 2014?
- 16:07I don't know.
- 16:14Would you turn to page 651?
- 16:24So, here there's a slide
- 16:26titled same test, a whole new approach.
- 16:29And the first line says Theranos runs
- 16:31any test available in central
- 16:33laboratories and processes all sample
- 16:35types.
- 16:37Was this statement true in January 2014?
- 16:42I I believe so. I don't know
- 16:46how much of our infrastructure had been
- 16:48operationalized in January, but
- 16:50essentially the concept that you could
- 16:52collect any type of sample and through
- 16:54Theranos have it processed
- 16:57um was certainly the business model.
- 17:01Uh was it true that Theranos was could
- 17:03run any uh or was running any test
- 17:06available in central laboratories?
- 17:10Theranos as a lab service offering, I I
- 17:12believe so because we had I think at
- 17:14that point reference labs set up to
- 17:16process some of the samples.
- 17:18So, you see there's some pictures above
- 17:20that statement with
- 17:22what looks like
- 17:24a collection device. Is that part of the
- 17:26Nanotainer
- 17:28or the capillary tube?
- 17:30Yes.
- 17:30That is the Nanotainer.
- 17:32Uh were you worried at all that this
- 17:36might create an impression that Theranos
- 17:38was using its um
- 17:41only its
- 17:43uh manufactured devices to run tests?
- 17:47Uh my
- 17:49general recollection is the point we
- 17:50were trying to make here is that you
- 17:52could do collection through finger stick
- 17:54and have an end-to-end lab service
- 17:57offering and that was the discussion
- 17:59that would accompany
- 18:01this type of slide.
- 18:02Okay.
- 18:03But when you when you say that was the
- 18:04discussion that would accompany it, do
- 18:05you recall
- 18:07accompanying the slide with that
- 18:09discussion you just described?
- 18:10I I I don't I don't have specific
- 18:12recollection of discussing this slide um
- 18:15but just sitting here now reading it um
- 18:19and knowing how we would generally
- 18:21describe what we were trying to do um
- 18:23that's my read on it.
- 18:26Okay, but you don't recall providing
- 18:28that sort of
- 18:29commentary in connection with this slide
- 18:30anyway.
- 18:31I I don't think that these slides were
- 18:33discussed with PFM.
- 18:35What what about any other investor?
- 18:37I don't think so.
- 18:38So so I guess to
- 18:40answer my question, you didn't you don't
- 18:42recall providing that sort of commentary
- 18:44that you just described
- 18:45um
- 18:46in connection with this slide with any
- 18:48in potential investor in Theranos.
- 18:50I I do not. I actually think this may
- 18:52have been on our website in the context
- 18:55of making that point, but I'm I'm not
- 18:57sure.
- 19:00Was the statement true in January 2014
- 19:04that Theranos was running any test
- 19:06available in central laboratories using
- 19:08one of your finger stick methods?
- 19:11I I don't think that's what this I I
- 19:13think the point that we were trying to
- 19:15make here is that you could collect
- 19:16finger stick for some tests and then
- 19:18also through Theranos as a lab service
- 19:20provider, we could accommodate any
- 19:22sample and do any tests so people
- 19:23wouldn't have to go to two different
- 19:26locations.
- 19:27So you're saying that the pictures at
- 19:28the top and the statement below it are
- 19:30actually two separate statements?
- 19:32I believe so.
- 19:33What what about the statement at the
- 19:34very top? Same tests, a whole new
- 19:36approach.
- 19:38Uh
- 19:39what was Theranos providing a whole new
- 19:41approach with respect to
- 19:43um
- 19:44running any test available in a central
- 19:45laboratory?
- 19:48Again, my my read on this sitting here
- 19:50now is that the the point we were trying
- 19:51to make was that we were introducing
- 19:53this finger stick methodology for blood
- 19:56testing
- 19:58more broadly and you could run any test
- 20:01available in in a central or through
- 20:03Theranos as a lab provider
- 20:05in a central lab.
- 20:07So So with the I I guess my question is
- 20:10just with Theranos as a central lab
- 20:11provider, was it was
- 20:14as a central lab provider, was it
- 20:15offering a whole new approach?
- 20:18We believed so because we were the first
- 20:20to introduce finger stick, the first to
- 20:22do upfront eligibility telling people
- 20:26how much they were going to owe, the
- 20:27first to create this consumer experience
- 20:28and we were trying to offer the ability
- 20:31to run any test through our laboratory
- 20:33when patients came into retail.
- 20:43You turned to 667.
- 20:47I said 57.
- 20:49667.
- 20:55You'll see there's a slide here with the
- 20:56title commercial.
- 20:58And
- 20:59the first line under that says key
- 21:01deployments and then there are a number
- 21:03of bullet points two which are emergency
- 21:06rooms, hospitals, and provider offices.
- 21:08And the second bullet point underneath
- 21:09is DoD.
- 21:11Do you see that?
- 21:12Yes.
- 21:13Was Theranos's technology deployed
- 21:16in emergency rooms, hospitals, and
- 21:18provider offices?
- 21:20No.
- 21:22Was Theranos's technology deployed at
- 21:25the DoD?
- 21:27I I believe the burn study was underway
- 21:29at multiple hospitals at this time, but
- 21:31not otherwise.
- 21:33Is that what you would have been talking
- 21:34about on this slide?
- 21:37No, sitting here now, my read on this is
- 21:39that this is our aspiration for what we
- 21:42thought all the key deployments would be
- 21:43in building out a commercial
- 21:45infrastructure.
- 21:46Was that your understanding at the time,
- 21:47too, that these were aspirational?
- 21:50I Again, I don't remember
- 21:53this specific slide, but yes, there's a
- 21:55lot of aspirational content in this deck
- 21:57of
- 21:58what we were trying to do with the
- 22:00company.
- 22:01And And I guess how
- 22:03how can you distinguish between what was
- 22:04aspirational at the time and what
- 22:06Theranos was actually doing at the time
- 22:07when we're when reviewing this slide
- 22:08deck?
- 22:10I I don't think these slides were
- 22:12intended to be stand-alone. They were
- 22:14a whole set of content that we would
- 22:17share as background material that were
- 22:19intended to be supplement with
- 22:20discussion and interaction.
- 22:23Okay, so do you Do you Do you recall
- 22:25ever providing that supplemental
- 22:26discussion and interaction with any
- 22:28potential investors?
- 22:29I'm
- 22:31I I know that we had multiple follow-on
- 22:34meetings in which investors would ask
- 22:36questions about
- 22:37areas of the business that they were
- 22:40interested in. I don't know that
- 22:41investors actually ever read this deck
- 22:43and and
- 22:48I guess
- 22:49just back my back to my question, do you
- 22:50recall ever having that sort of
- 22:52discussion about this deck with any
- 22:54investors? Like whether whether this
- 22:56whole thing or or a subset of it.
- 22:58I don't believe an investor ever asked a
- 23:00question about the deck that I know of.
- 23:04Did you ever provide a subset of this
- 23:06presentation to any potential investors?
- 23:09I don't know.
- 23:11Would it surprise me if you did?
- 23:14Not necessarily. I I don't have memory
- 23:16of doing that. Um
- 23:19If you were providing um to the extent
- 23:21that you did provide
- 23:23uh a subset of this presentation to any
- 23:25potential investors, how would that
- 23:27potential investor know
- 23:29what was aspirational versus what was
- 23:32actually the truth at the time that
- 23:35they were
- 23:36reviewing the presentation?
- 23:38In general, my understanding is that
- 23:40these materials were sent after we had
- 23:42meetings with
- 23:45investors or potential investors or
- 23:47partners and they followed discussions
- 23:49about what we were trying to do, who we
- 23:51were as a company,
- 23:53um and were intended as background
- 23:55material on
- 23:57exactly what we were trying to do.
- 24:01Turn to 682
- 24:04and 683.
- 24:06Can I just ask a quick question?
- 24:07Yes, sure.
- 24:08So, this one's in your in these meetings
- 24:10that you had with investors and
- 24:12potential investors,
- 24:15did you talk about what was aspirational
- 24:18at what you wanted to achieve?
- 24:21Yes.
- 24:22And did you talk about specifically the
- 24:23technology
- 24:25and blood draw and what was in place at
- 24:27that time versus what was aspirational?
- 24:29Was there a clear delineation between
- 24:31those two?
- 24:33We tried to do that. Looking back on it
- 24:36now and especially in the case of PFM, I
- 24:39wish we had done that even more
- 24:41explicitly including in writing. We
- 24:42didn't have the same type of systems in
- 24:44place we have now on things like sending
- 24:46out materials, but we thought we had at
- 24:48the time.
- 24:49And what specifically do you wish you
- 24:51would have communicated to PFM at the
- 24:53time?
- 24:55What I I I think we did communicate,
- 24:57which is phase one, phase two, um what
- 25:01we were doing in phase one, what the
- 25:02business model was, what technology we
- 25:04were using, and what we were doing in
- 25:07phase two, and what technology we were
- 25:09intending to use in phase two.
- 25:11I I know that we also really thought we
- 25:13were closer to phase two than we were.
- 25:17J- I just want to make sure I'm
- 25:18understanding. So, you Is it your
- 25:19testimony that you did communicate phase
- 25:21one and phase two to PFM, or you wish
- 25:23you would have conveyed phase one and
- 25:25phase two to PFM?
- 25:26It's my testimony that I think I did. We
- 25:28We did. Theranos did. I I don't know if
- 25:30it was me specifically. And it's also my
- 25:33testimony that, you know, I I understand
- 25:35if you take this document in isolation,
- 25:38um that
- 25:39we could have done a much better job in
- 25:42creating documents that we were sending
- 25:43to people. We We didn't intend these
- 25:46documents to be stand-alone, and and you
- 25:49know, sitting here now, I know we could
- 25:50have been much better at the way we
- 25:52prepared materials and shared them, um
- 25:55than we were at the time.
- 25:57So, is it your testimony that in the
- 25:58discussions, the meetings that you had
- 26:00with PFM, that you did describe phase
- 26:04one and phase two, but that that's not
- 26:06was what was That was not necessarily
- 26:08reflected here in the document that
- 26:09we're looking at.
- 26:10Y-
- 26:11Yes, it's my testimony that I believe in
- 26:14the meetings that we had with PFM, we
- 26:15did describe phase one and phase two.
- 26:18A- And additionally, in looking at the
- 26:20slide deck, I don't think this slide
- 26:22deck does a good job of describing that
- 26:24on a stand-alone basis.
- 26:27Okay. Thank you. Who Who bears
- 26:28responsibility for the failures of this
- 26:30plan deck?
- 26:32I I- It's my understanding that PFM
- 26:34understood, based on what we at least
- 26:37tried to communicate, um
- 26:40or or I guess I I I had thought that we
- 26:42had communicated, um
- 26:44that this was an internal deck that we
- 26:47were sharing with them for background
- 26:48purposes, not that
- 26:50it was intended to operate as a
- 26:52standalone document. And um
- 26:56I I wish we had done a much better job
- 26:57of, you know, documenting that in terms
- 27:00of the communication with them, but we
- 27:02had at least intended to be clear when
- 27:03we sent it that this was
- 27:05supposed to be an internal sort of
- 27:07compilation of materials that we were
- 27:09sharing for background purposes.
- 27:12Sure, I understand that, but I guess you
- 27:13know, I think you described it as you
- 27:15you um
- 27:16you know, you sort of wish it had it it
- 27:18had it it had been communicated in a
- 27:19different way.
- 27:20Yep.
- 27:21Um
- 27:22whose responsibility would it have been
- 27:23to communicate in a different way to PFM
- 27:26at that time?
- 27:29Um
- 27:32well, I I mean, in retrospect, I I think
- 27:34we should have in writing documented
- 27:37what I think we had said to them, which
- 27:39was that this was a compilation of
- 27:40internal materials that we would share
- 27:43and exactly what what the deck was. I
- 27:45I think we we at least attempted to
- 27:47communicate that verbally, um but we
- 27:50don't have good record of that.
- 27:52Well, who's the we in that sentence, I
- 27:54guess? Is it Is it you and Sunny? Is it
- 27:55Is it Theranos the company? Who?
- 27:57Theranos the company. I I can't remember
- 27:59the specifics of the conversations with
- 28:01PFM and
- 28:02um
- 28:03you know,
- 28:04the moment when they they asked for the
- 28:06deck. I I just know my general
- 28:08understanding of what happened in the
- 28:10context of sending this material.
- 28:12Okay, so can you point to anyone who
- 28:14would be who who you think bears
- 28:16responsibility for uh
- 28:19for the way in which this deck was sent
- 28:20and communicated to PFM to PFM?
- 28:24Um
- 28:25well, I
- 28:26I mean,
- 28:27Theranos, myself, Sunny in the context
- 28:30of the engagement
- 28:32with PFM. We were the principals
- 28:34interacting with them.
- 28:35Okay, so
- 28:36um
- 28:37I I I mean, I'm assuming that Theranos
- 28:38is an entity and you and Sunny are
- 28:40individuals. Other than you and Sunny,
- 28:42are there any other individuals you feel
- 28:43that bear responsibility for that?
- 28:46For what?
- 28:47For for for um
- 28:49you know as you said sort of the the the
- 28:51way in which the slide deck was
- 28:52communicated to PFM.
- 28:56Um
- 28:57I don't I don't know if anybody else had
- 28:59had an interaction with them around it
- 29:00and this was
- 29:02the way the company was operating at at
- 29:04this time generally and
- 29:06we believed at that time that the people
- 29:08who we were interacting with understood
- 29:09what the content we were sharing was.
- 29:17If you turn to um 682 and 683 and I
- 29:20think you're on 682 right now.
- 29:23We're also looking at uh 683. We're also
- 29:25looking at 682 as well. What were you
- 29:28trying to convey in these two pages?
- 29:32Have you Have you seen these slides
- 29:34before?
- 29:36Whether it's outside of this
- 29:37presentation
- 29:38or not.
- 29:40Um
- 29:43I have. I I remember them as being from
- 29:45the slide deck we were using with our
- 29:47retail partners to talk about what the
- 29:50process would be at retail for doing a
- 29:52finger stick.
- 29:54So here are you trying to convey that
- 29:57where it says lab today on 682,
- 30:00uh are you trying to convey that you
- 30:02know today blood testing is being done
- 30:04via
- 30:06venipuncture using a syringe?
- 30:09Is that
- 30:10what you're trying to convey by the
- 30:11first picture?
- 30:12I don't know. I I think in general these
- 30:15were slides describing finger stick at
- 30:18retail.
- 30:22Okay. Um so what what is the message
- 30:25that you're portraying by 6 um 3682?
- 30:29Do you want to take a minute to look at
- 30:31the slides before and after?
- 30:33Sure.
- 30:53Sitting here now, my read is that it's a
- 30:54description of what finger stick testing
- 30:56would be like
- 30:58at Walgreens.
- 31:01Is that is that meaning aspirationally?
- 31:04I I mean, my memory is that most of this
- 31:07deck is aspirational.
- 31:09But yeah, this is I mean, it starts with
- 31:11a
- 31:12sort of Walgreens store and then the
- 31:14process of doing the collection and what
- 31:17that process would be like and I
- 31:19again think these slides were from
- 31:21actually a retail deck on what the
- 31:24service offering would be.
- 31:27So, turning to 685,
- 31:32there's a slide titled New Possibilities
- 31:35in Lab and it says
- 31:37under routine, specialty, and esoteric
- 31:40testing,
- 31:41all 1,000 plus currently run tests, CPT
- 31:44codes are available through Theranos.
- 31:47And again, Theranos runs any test
- 31:48available in central laboratories.
- 31:51Was that a true statement in January
- 31:532014 that all 1,000 plus currently run
- 31:56tests or CPT codes are available through
- 31:58Theranos?
- 32:01Again, I think it's the same comment
- 32:03that the whole range of tests could be
- 32:04run through Theranos' lab and I I think
- 32:07that was true in January 14, but
- 32:10I'm not sure how much of that had been
- 32:11operationalized in January 14 cuz we'd
- 32:14only been open for a couple months at
- 32:16that point.
- 32:17And so, this would have been including
- 32:19tests being run on the modified
- 32:20commercially available machines, tests
- 32:22being run on the unmodified commercially
- 32:24available machines, and also tests being
- 32:26sent out to reference labs.
- 32:27That's right.
- 32:30Was that conveyed to potential investors
- 32:32when you were talking about how 1,000
- 32:35plus currently run tests were being
- 32:37offered through Theranos Labs.
- 32:40I don't know if that we were ever
- 32:42talking specifically about this. Um I I
- 32:45thought that we had and talked about
- 32:48what we were running and that we were
- 32:50including reference lab capabilities in
- 32:53our service offering in phase one.
- 32:55When you say you thought you had
- 32:56conveyed that, do you know that you
- 32:58conveyed it to any potential investors?
- 33:00Again, I don't remember specific
- 33:02conversations on on these points.
- 33:05Okay, going to 698 then.
- 33:22There's a slide here titled validation
- 33:24of Theranos.
- 33:26And at the bottom of the slide it says
- 33:28excerpts from Johns Hopkins due
- 33:30diligence and technology validation. Do
- 33:32you see that?
- 33:33Yes.
- 33:35Did Johns Hopkins conduct a validation
- 33:37of Theranos' technology?
- 33:41Um
- 33:42as I understand it, they did for
- 33:44Walgreens.
- 33:46What do you mean as you understand it
- 33:48they did for Walgreens?
- 33:50Um Walgreens team would talk about the
- 33:52Johns Hopkins validation meaning that
- 33:54Johns Hopkins had signed off on
- 33:57um
- 33:58sort of the architecture of the
- 34:00technology as a platform that could do
- 34:02all these things.
- 34:06Earlier in your testimony, you testified
- 34:08that no devices were ever given to Johns
- 34:10Hopkins. Do you remember that?
- 34:13We brought one to the meeting, I
- 34:15believe. Um but yes, I don't think
- 34:17Theranos independently shipped devices
- 34:19to Hopkins.
- 34:20Okay, so how did Johns Hopkins conduct a
- 34:23validation of your technology if it
- 34:24didn't have access to your your device?
- 34:27Again, my understanding is that this was
- 34:29really looking at the design and
- 34:30architecture of the technology, would it
- 34:33be capable of doing something that no
- 34:35other point-of-care technology had ever
- 34:38been able to do?
- 34:40You also testified earlier that your
- 34:42understanding of validation included
- 34:43such factors as linearity and precision
- 34:46and test specificity. Do you remember
- 34:48that?
- 34:49The assay or chemistry validation, yes.
- 34:51Okay. Do you remember Johns Hopkins
- 34:53doing any of that?
- 34:55Uh study on your on of your either your
- 34:57test or your devices?
- 34:59No.
- 35:00Wait. Wait. Wait.
- 35:01That you any of the assays you mean as
- 35:03opposed to the device?
- 35:05So, I'm asking her, do you under do you
- 35:08remember Johns Hopkins doing any
- 35:11um
- 35:12work on either validating the test or
- 35:16the devices under that framework, what
- 35:19we just talked about? Looking at
- 35:21linearity, precision, test specificity.
- 35:24They reviewed some of that data, um they
- 35:26did not perform validations themselves.
- 35:29They just reviewed data.
- 35:32Okay, turn to 700.
- 35:36Can I ask another question on
- 35:38698? Do you see the line above that it
- 35:40says
- 35:41Theranos' lab infrastructure is
- 35:43validated under FDA, ICH, and World
- 35:46Health Organization guidelines?
- 35:48Mhm.
- 35:49Uh
- 35:50was that a true statement as of January
- 35:512014?
- 35:56I don't know.
- 35:57Um
- 35:58I I know that our understanding of the
- 36:01standards that we were using to validate
- 36:03our LDTs, our lab-developed tests,
- 36:05changed over time. And I think this is
- 36:07what that is referring to, but
- 36:10um we later
- 36:12learned that we should be using
- 36:13different standards.
- 36:15All right. What what what do you take
- 36:16lab infrastructure to mean?
- 36:20I I'm not sure. I don't know.
- 36:23I I I could guess. Yes or no?
- 36:27Uh I mean
- 36:28Is it Is is is the is the sentence here
- 36:32Theranos' lab infrastructure
- 36:34is validated under FDA, I C H, and World
- 36:36Health
- 36:37World World Health Organization
- 36:39guidelines?
- 36:40Um a statement that
- 36:42Theranos' TSPU has been validated under
- 36:44these guidelines?
- 36:47No. I I'm sitting here now, my read is
- 36:49that it's
- 36:50talking about the standards that we were
- 36:53using for validation of the
- 36:54lab-developed tests.
- 36:56I get all right.
- 36:57Were lab-developed tests often called
- 36:59infrastructure?
- 37:01I don't know.
- 37:02Did you ever use that word to call
- 37:04in referring to lab-developed tests?
- 37:06I I don't know.
- 37:08Can you recall an instance where it was?
- 37:10I can't.
- 37:13Who drafted that slide?
- 37:16I don't know.
- 37:17I think it again, like one of these
- 37:18slides, it's it's an old slide that was
- 37:21carried through in a lot of decks or
- 37:23and/or updated over time.
- 37:26If you turn to 700,
- 37:30there's a slide titled products.
- 37:32Mhm.
- 37:33And here under devices, there's a bullet
- 37:35point that says mini lab and 4S for
- 37:37automated processing. Do you see that?
- 37:40Yes.
- 37:41These weren't the only devices that were
- 37:43used by Theranos for patient testing,
- 37:45were they?
- 37:47I I don't think either of them were used
- 37:48for patient testing.
- 37:50Okay. What Why didn't you include, for
- 37:51instance, 3.5? That was being used for
- 37:54patient testing.
- 37:56I
- 37:56I believe that this is a specific slide
- 37:59talking about what products the company
- 38:01wanted to develop on a go-forward basis.
- 38:04And
- 38:05what's your basis for that belief?
- 38:07I I generally recognize it, and I
- 38:11generally have memory that we were
- 38:12trying to distinguish sort of products
- 38:14from the clinical lab, that Theranos was
- 38:16developing products, and it also was
- 38:18operating a lab, and that this part of
- 38:20the discussion was on the the technology
- 38:22or the products that we were trying to
- 38:23build.
- 38:30Do you Did you ever talk to investors
- 38:33and show them this particular slide?
- 38:36Again, I I don't remember ever having
- 38:38conversations with investors about the
- 38:40slide deck.
- 38:42Did you But did you ever have any
- 38:44conversations with investors about this
- 38:46particular slide?
- 38:47I don't think so.
- 38:48What about 701, which is the next page?
- 38:52There are pictures
- 38:55of a number of things under the title
- 38:58overview of Theranos systems.
- 39:01Under Theranos analyzers is there's a
- 39:03picture of two analyzers there. What are
- 39:05these pictures of?
- 39:08Um one is of the the 3-series device. I
- 39:11don't know if it's a 3.0 or 3.5, and the
- 39:13other one is one of the 4-series devices
- 39:16in mini labs.
- 39:17Okay, so here under you know, you're
- 39:20you're actually showing pictures of
- 39:22Theranos analyzers. Why didn't you
- 39:23include other machines that you were
- 39:25using, including the commercially
- 39:27available machines here?
- 39:29Again, I don't think this part of the
- 39:31presentation, these slides, were used to
- 39:33support anything about the clinical lab.
- 39:35I think this was talking about the
- 39:36proprietary technologies that we were
- 39:38working to develop
- 39:39for distributed testing.
- 39:41Did you think that this might give the
- 39:43wrong impression that the only Theranos
- 39:45analyzers Theranos was using were its
- 39:47own proprietary devices, and that
- 39:49Theranos wasn't using commercially
- 39:50available machines to conduct testing?
- 39:52Not at the time, cuz we weren't using
- 39:54these decks. Um
- 39:58for the purpose of trying to provide a
- 40:00comprehensive overview of the company.
- 40:02Um but again, were I preparing this
- 40:04content now, we're we're being very
- 40:06careful to prepare this content very
- 40:07differently now.
- 40:11So do you think it could have been made
- 40:12clearer that you were not providing an
- 40:14overall uh of what the company was doing
- 40:18or using and that
- 40:20uh you could have been more specific as
- 40:22to the analyzers Theranos was using at
- 40:24the time.
- 40:26At the time we did not think that these
- 40:28slides were
- 40:30ever going to be looked at as
- 40:32stand-alone descriptions of what we were
- 40:34doing. We thought they were
- 40:36um
- 40:37tools to facilitate different parts of
- 40:39the discussion.
- 40:41Now again, we are taking a very
- 40:43different approach to how we're
- 40:45preparing any content.
- 40:47Why don't you turn to 733?
- 40:49Sorry, before we leave the slide again,
- 40:50just the the slide is titled overview of
- 40:53Theranos systems.
- 40:54Mhm.
- 40:55So sorry, is that a yes?
- 40:56Yes.
- 40:57Uh i- i- i-
- 40:58I mean is it your basic testimony that
- 41:00this isn't an overview of Theranos
- 41:01systems, it's a overview of Theranos's
- 41:04planned systems?
- 41:06Um Theranos systems was the word that we
- 41:09generally used to describe the
- 41:11proprietary family of technologies that
- 41:13we were developing with many lab. And
- 41:16yes, it's my general memory that this
- 41:19this deck was about was aspirational. So
- 41:22these were the technologies we wanted to
- 41:23take into the FDA and distribute on the
- 41:27market, but obviously had not done that
- 41:29yet.
- 41:31Just one other follow-up Mr. Holmes. Um
- 41:33you just said prior to Mr. uh Cole had
- 41:36asked question that the deck was a tool
- 41:39to facilitate discussion.
- 41:41Yeah.
- 41:41Um so I know you said that you didn't go
- 41:43over the deck or other than that one
- 41:45slide.
- 41:47Did you have the deck there in the
- 41:48meeting and you were going through it
- 41:50with PFM or how did that work?
- 41:53Um
- 41:55I I don't know that we had the deck with
- 41:56us. Um it's my general understanding
- 41:59that we did not go through a deck with
- 42:01PFM at all. I think that on a computer,
- 42:03I don't know if it was mine or
- 42:05in fact I'm probably was not mine cuz I
- 42:07generally didn't bring computers to
- 42:08meetings, but a slide was put up to
- 42:11support a conversation and I generally
- 42:14understand that after that PFM asked,
- 42:16"Could you send the deck that slide is
- 42:18from?" And we sent this big deck.
- 42:22So, when you were having the discussions
- 42:24with PFM employees, did
- 42:27did you have the deck in front of you
- 42:30even though you weren't projecting it or
- 42:31any of the slides from it? Did you have
- 42:34it as kind of a tool that you would use,
- 42:36either you or Mr. Balwani would use to
- 42:39facilitate the discussion that you
- 42:40previously testified to?
- 42:41I I don't think it was up on the screen.
- 42:44Um I think it was literally brought up
- 42:45with a slide to facilitate discussion. I
- 42:48I
- 42:49can infer from that that it was on a
- 42:51computer that was in the room uh at the
- 42:53time of the meeting.
- 42:54Okay.
- 42:55I guess
- 42:56Did you Did you have a copy for your of
- 42:58the slide deck for yourself to use as
- 42:59sort of a
- 43:00set of talking points?
- 43:01No.
- 43:02Did you generally have a prepared set of
- 43:03talking points when meeting with
- 43:05investors?
- 43:06No.
- 43:07What did you use to sort of guide the
- 43:09discussion?
- 43:10Um
- 43:12I I I would generally speak um in in
- 43:15free form because the part of the
- 43:17conversation that I had was was our
- 43:18vision. So, it was about talking about
- 43:20who we were, what we were trying to do,
- 43:22and then I would talk about
- 43:24the inventions. And then from there um
- 43:28there was generally follow-on
- 43:29discussions where people would do
- 43:30diligence and I for the most part was
- 43:32not involved in those uh next set of
- 43:34conversations.
- 43:36Because they were with Mr. Balwani or
- 43:38someone else from Theranos?
- 43:39Yes.
- 43:40Just
- 43:41if if you didn't use the deck during the
- 43:44meeting and you didn't use it yourself
- 43:47as a tool to facilitate the discussion,
- 43:49then my question would be, what then is
- 43:50the point of the deck?
- 43:53The The deck was a
- 43:55um
- 43:56amalgamation of slides
- 43:58that Theranos had. It was used by
- 44:00different teams, different people for
- 44:02different purposes. It's It's literally
- 44:05a set of marketing content, a set of
- 44:06content from the website, a set of
- 44:08content about the labs, a set of content
- 44:10about our retail relationships, you
- 44:12know, data, and it was a working tool
- 44:15that different people throughout the
- 44:16company would use if they needed to pull
- 44:19a piece of information to support a
- 44:21discussion. So, if they wanted, for
- 44:23example, a picture of the system if they
- 44:25were trying to describe the system, they
- 44:27would pull that slide from the deck to
- 44:29support discussion.
- 44:30So, your testimony as I understand it is
- 44:34you had this deck already in place and
- 44:37there was a discussion during the
- 44:38meeting with PFM in which you pulled out
- 44:41one slide, projected that, and then PFM
- 44:43from that point said, "Hey, can we get
- 44:45later on said, can we get a copy of the
- 44:46deck that you used?"
- 44:47Yes.
- 44:48Okay.
- 44:50Who pulled up that slide?
- 44:52I don't know.
- 44:53It wasn't Mr. Balwani?
- 44:56I again, I don't know. I I know that I
- 44:58generally didn't bring computers to
- 44:59meetings, so probably, but I don't
- 45:01remember it specifically.
- 45:03Okay. If you go to page 733,
- 45:08there's a slide titled clinical data
- 45:11and then a whole section full of slides
- 45:14behind it.
- 45:16Yes.
- 45:17You see that?
- 45:22And let's just take a look at a specific
- 45:26slide.
- 45:27754.
- 45:36Looks like there's a chart for ferritin.
- 45:39Do you see that?
- 45:40Yes.
- 45:41What is this chart
- 45:44supposed to convey?
- 45:47Um data that we thought was
- 45:49representative
- 45:50as to the performance of the the
- 45:52chemistry
- 45:54that was
- 45:56designed to be able to handle small
- 45:57sample volumes.
- 46:00Okay, so so take me through what's being
- 46:03compared here. So,
- 46:05is this a correlation graph?
- 46:08Uh it's a method comparison graph.
- 46:10A method comparison graph. So, what are
- 46:11you comparing here?
- 46:14You're comparing the Theranos assay to
- 46:16one by Elpco
- 46:18uh
- 46:20uh
- 46:20diagnostics, I think is their name.
- 46:22And what are each of these assays being
- 46:25tested on? What What device or platform
- 46:28are they being tested on?
- 46:30Um I believe ferritin was on the
- 46:32Theranos TSPU, and the Elpco is on a
- 46:35kit.
- 46:37Okay, and the kit, is that What is that?
- 46:39Is that like a manual kit?
- 46:43I I think so. I don't know for sure.
- 46:45Okay, so you're comparing the
- 46:47performance of the Theranos assay on the
- 46:49TSPU versus um
- 46:52a reference assay using
- 46:55some other platform. Is that fair?
- 46:57Yes.
- 46:58Okay. And so is this trying to show that
- 47:00the Theranos method is quite close to
- 47:03the reference method?
- 47:06It's showing what the concordance is. At
- 47:08the time, we thought this was really
- 47:10good. Uh today, we actually wouldn't
- 47:13accept this as being as good as we we
- 47:15thought it was.
- 47:17Why do you say that?
- 47:20Um
- 47:21we we used to believe that cutoffs like
- 47:24R squared and about this many samples
- 47:26were sufficient to show validation of a
- 47:29test. And we have much more
- 47:31comprehensive uh mechanisms in place
- 47:33right now for the standards to which
- 47:35we're validating.
- 47:36Okay.
- 47:37And so you understood in January 2014
- 47:40though that ferritin wasn't actually
- 47:42being tested on the TSPU in patient
- 47:44testing, though, correct?
- 47:47I don't know that I understood that in
- 47:49January 2014. Um I I knew there was a
- 47:52limited number of tests on the TSPU in
- 47:54the in the
- 47:55Would it surprise you if you knew that
- 47:57ferritin was being tested instead on a
- 47:59commercially available machine at that
- 48:01time?
- 48:02I I don't think I would have known that.
- 48:04Um but it wouldn't surprise me if it was
- 48:06being tested on a commercial machine.
- 48:08Do you think that the fact that you're
- 48:09including these correlation graphs that
- 48:12compare the Theranos methods to
- 48:14reference methods and Theranos methods
- 48:17being on the TSPU would uh create the
- 48:20impression to people who were reviewing
- 48:23these slides that Theranos was using its
- 48:25TSPU for all of these tests at that
- 48:28time?
- 48:29Why?
- 48:30Um because these data were intended to
- 48:33reflect the fact that we had worked on a
- 48:36large number of chemistries
- 48:38to
- 48:39um handle small sample volumes and that
- 48:41we would work to bring those up in the
- 48:43lab over time. This was not intended to
- 48:45reflect the clinical lab.
- 48:47This This is all under a section called
- 48:48clinical data.
- 48:49Yes.
- 48:50right? I get Can you just differentiate
- 48:52between in your mind difference between
- 48:54clinical lab and clinical data?
- 48:57I I believe clinical data is the term to
- 48:59reflect plots when you're using actual
- 49:02clinical samples for the plot as opposed
- 49:04to some of the experiments that you were
- 49:06referencing earlier, which are not done
- 49:08on on actual live samples. They're done
- 49:10on
- 49:11um
- 49:13derived materials. Um
- 49:15this part of the discussion
- 49:17um was broadly about the the assays that
- 49:20we were developing to the extent that we
- 49:22showed this data.
- 49:25So are you saying that patient samples
- 49:27were being used uh in order to do this
- 49:30method comparison?
- 49:32Yes.
- 49:33So So like leftover material from a
- 49:36uh from a test run on a on a traditional
- 49:38machine could be used in to
- 49:41to test a Theranos assay. Is that right?
- 49:43So the the last part of an assay sort of
- 49:47validation process, as I understand it,
- 49:49is the method comparison and that's
- 49:51where you take an actual sample and
- 49:54compare it to methods. The rest of the
- 49:56steps like linearity or precision are
- 49:59not done with actual patient samples.
- 50:02And that's why it says clinical data.
- 50:04This is the that last step where you're
- 50:05actually doing the comparison with the
- 50:07clinical sample.
- 50:10All right, we'll take a short break. Uh
- 50:12we're off the record at 2:06 p.m.
- 50:22We're back on the record at 2:20 p.m.
- 50:25Ms. Holmes, did you have any substantive
- 50:26conversations with the SEC staff during
- 50:28the break?
- 50:29I did not.
- 50:31Did you
- 50:32ever send a subset of the
- 50:36internal slide deck something similar to
- 50:38exhibit 256 to
- 50:41I don't know.
- 50:44Would it surprise you if you did?
- 50:46No.
- 50:48Why not?
- 50:50The
- 50:50it was a the tool that we used uh
- 50:53in supporting discussions.
- 50:57But you had earlier said that uh
- 51:00you wouldn't provide the slides without
- 51:02some explanation
- 51:04about the slides.
- 51:05No, I'm I'm sorry, what I was trying to
- 51:07say
- 51:07I don't think that's what she said but
- 51:08please continue.
- 51:09Yeah, I what I was trying to say was
- 51:10that the the slides were
- 51:13um
- 51:14not created to be standalone material.
- 51:19Okay, so what were they created for?
- 51:22They were created to support
- 51:23discussions.
- 51:25Okay, I don't know how that's any
- 51:26different from what I just asked you.
- 51:29I'm sorry, maybe I misunderstood the
- 51:31question.
- 51:31I had understood you to say that the
- 51:34slide deck wasn't meant to be sent to
- 51:37other
- 51:38other people such as potential investors
- 51:40without an explanation for those slides.
- 51:44Isn't of wasn't that the testimony.
- 51:46I'm maybe I
- 51:49didn't communicate clearly. I What I was
- 51:51attempting to communicate is that I'm
- 51:54when those slides were created, they
- 51:56were not created to operate in a
- 51:59standalone way.
- 52:01We would share them
- 52:03and generally with people with whom we
- 52:05were in active discussion.
- 52:08Do you recall sending materials more
- 52:10generally with with the connected day
- 52:12exhibit 256 or otherwise?
- 52:15I I I recall that he was advising
- 52:18me
- 52:19and us in the early days of my
- 52:21relationship with him. He
- 52:23even acted as my counsel for a period of
- 52:25time.
- 52:27So we we shared a lot of information
- 52:28with him.
- 52:30Did you share any information with him
- 52:31in connection with obtaining potential
- 52:34investments in Theranos?
- 52:36I'm we shared information with him in
- 52:39the context of the C2 round and the
- 52:41people who
- 52:43we were
- 52:44I'm talking to and I remember asking for
- 52:47his advice on you know, what information
- 52:49would make sense to to share.
- 52:54The
- 52:58I guess is it your testimony that you
- 53:00retained to provide you with legal
- 53:01advice on that issue?
- 53:04I'm
- 53:05I I'm I'm just trying to be careful
- 53:06about how
- 53:07Yeah, I was
- 53:08as Holmes' lawyer
- 53:10for a significant amount of time
- 53:12on a number of issues.
- 53:14And
- 53:16we then are talking about whether this
- 53:17goes into it or not. Let Let us have one
- 53:19one second. There's a lot of stuff that
- 53:21was clearly attorney-client privilege.
- 53:23We're off the record at 2:23 p.m.
- 53:26Yeah, just have really good
- 53:27conversation.
- 53:31We're on the record at 2:33 p.m. Ms.
- 53:33Holmes, did you have any substantive
- 53:35conversations with the SEC staff during
- 53:37the break?
- 53:37No.
- 53:38So just to follow up on a question,
- 53:40did you understand Did you have an
- 53:42understanding in 2014 that certain
- 53:45materials were provided in connection
- 53:47with his potential investment in
- 53:48Theranos?
- 53:49Yes or no.
- 53:50Uh um
- 53:52If you can answer yes or no.
- 53:54I I I understood that they were
- 53:56generally being provided for advice
- 53:58um in connection with the C2 round that
- 54:01we were um
- 54:03that we were working toward.
- 54:05What materials were those?
- 54:07I don't remember specifically. I know
- 54:08that he had access to a number of
- 54:10documents that we sent documents to him.
- 54:12Uh do you remember who at Theranos sent
- 54:14him those documents?
- 54:16I don't um but I I
- 54:19um would assume that I sent some of them
- 54:22to him.
- 54:24Do you know if he passed those materials
- 54:26on to
- 54:27potential C2 investors?
- 54:30I don't know if he passed them on. I
- 54:32think he may have shown materials that
- 54:35he had to certain potential investors.
- 54:38Did Did you understand at the time that
- 54:40materials were being provided to him
- 54:42that he was intending to show those
- 54:44materials to potential investors?
- 54:47No, I think he did that later.
- 54:50Did
- 54:51Did he ever attend um meetings that you
- 54:53had with
- 54:55potential C2 investors at Theranos?
- 54:57Yes.
- 54:58Uh with anyone?
- 54:59Yes.
- 54:59Uh
- 55:00would that include um
- 55:02J- just for clarity's sake since there's
- 55:04a
- 55:05Uh sure, Cox Investments.
- 55:07Yes.
- 55:07Um who who else did he attend with?
- 55:11Um he was at one of the meetings with uh
- 55:16um it wasn't at Theranos, but it was um
- 55:19about investing in Theranos um and
- 55:23uh he may have been at at others as
- 55:25well.
- 55:26Uh did he attend a meeting with um
- 55:29representatives from the Niarchos
- 55:30Foundation?
- 55:32Yes.
- 55:33Uh
- 55:34Yes, it it
- 55:37In a
- 55:37Actually, I think so. You may have been
- 55:38on the phone. I'm not sure.
- 55:41Um
- 55:43did
- 55:45in any of those meetings
- 55:48do you recall presenting a selection of
- 55:50the slides that we saw in exhibit 256?
- 55:54I don't remember that, no.
- 56:02Earlier in your testimony
- 56:05you testified that BDT Capital was hired
- 56:08as a financial advisor to Theranos. Do
- 56:09you remember that testimony?
- 56:11As an as an advisor initially, yes. Or
- 56:14that we engaged with them. I don't know
- 56:15if we hired them per se.
- 56:18Okay. And in late 2014, you understood
- 56:21that they were considering to invest in
- 56:22Theranos, that they were a potential
- 56:24investor as well, correct?
- 56:26I did.
- 56:28I'm going to hand to you what's been
- 56:29marked as Theranos exhibit 266.
- 56:40Is it a 266?
- 56:42It purports to be a December 6 I'm
- 56:45sorry, December 19th, 2014 email from
- 56:49Elizabeth Holmes to Sunny Balwani.
- 56:52Subject line is forward project test
- 56:54company overview memo version 025.pdf
- 56:59with starting Bates number THPFM
- 57:020003891168.
- 57:07With an attachment with Bates number
- 57:09starting
- 57:11THPFM 0003891169.
- 57:16Have you seen exhibit 266 before?
- 57:21I don't know. I I don't remember it, but
- 57:23I don't have reason to doubt the email
- 57:25exchange.
- 57:26What is exhibit 266?
- 57:30Um it looks like an email exchange.
- 57:33Yeah, I'm with an attachment from you.
- 57:42Did you receive the email on December
- 57:4518th, 2014
- 57:47from
- 57:49on or about
- 57:51December 18th, 2014?
- 57:55Again, I don't remember it, but I assume
- 57:56I did.
- 57:58And you also received um
- 58:00a following email around the same date
- 58:02from
- 58:04It looks like I did, yes.
- 58:07Do you understand to where the addresses
- 58:09on these emails
- 58:12Yes.
- 58:14So, you'll see here uh at the bottom of
- 58:161168 on exhibit 266, there's an email
- 58:21from to you.
- 58:22And he says, "Elizabeth, attached is the
- 58:25preliminary draft of our company
- 58:26overview that we would plan to send to
- 58:28the pre-approved co-investor targets."
- 58:30Do you see that?
- 58:32I do.
- 58:36Did you understand that information that
- 58:38they were including on this memo that
- 58:40he's attaching to this email was based
- 58:42on conversations that you had with you
- 58:43and Mr. Balwani?
- 58:47Again, I I don't remember
- 58:49uh receiving this email and I I don't
- 58:50know that I ever read the attachment.
- 58:54Had you had discussions with Capital
- 58:56prior to December
- 58:5918th, 2014?
- 59:01Yes.
- 59:02And in those discussions, had you
- 59:04described Theranos'
- 59:07vision and its operations?
- 59:10Yes.
- 59:15Did you understand by the time of this
- 59:17email that Capital had prepared a memo
- 59:20in order to send out to potential
- 59:22co-investors?
- 59:25I I don't know. My My memory generally
- 59:27is that we
- 59:29were deciding whether or not to have
- 59:30best and and ultimately decided not to
- 59:32proceed.
- 59:34Did you have any discussions with
- 59:35Capital about them going out to find
- 59:39co-investors to invest together in
- 59:41Theranos with
- 59:43Um my memory is that they already had
- 59:45entities that were interested in
- 59:47investing, um
- 59:48but I don't remember specific
- 59:50conversations about that.
- 59:52Okay, so in Elizabeth's email at the
- 59:54bottom, he says, "Feel free to make any
- 59:56changes, edits." Do you see that?
- 59:58Yes.
- 1:00:00Did you end up making any changes to the
- 1:00:02memorandum that he attached and sent and
- 1:00:05Did you ever send that back to the
- 1:00:07Capital?
- 1:00:09Again, I don't recognize the document,
- 1:00:11so I don't know that we ever went
- 1:00:12through it. I think we ended up deciding
- 1:00:14not to proceed with the financial
- 1:00:16investment from
- 1:00:18Okay, and after Elizabeth's email, then
- 1:00:21he sends another email and she attaches
- 1:00:23instead of a PDB PDF version of the
- 1:00:25memorandum, she sends a Word version of
- 1:00:27the document. Do you see that?
- 1:00:30I do.
- 1:00:30So, she was intending to make it easier
- 1:00:32for you and Mr. Balwani or at least for
- 1:00:34you to make changes to the document,
- 1:00:35correct?
- 1:00:36Yes.
- 1:00:37Okay, and then you send it You forward
- 1:00:39the email to Mr. Balwani. Do you see
- 1:00:41that at the top?
- 1:00:42Yes.
- 1:00:42What was your purpose in sending it to
- 1:00:44Mr. Balwani?
- 1:00:46I don't know. I can't remember receiving
- 1:00:47this email.
- 1:00:53You can keep that in front of you.
- 1:00:56I'm going to hand to you what's been
- 1:00:58marked Theranos Exhibit 267.
- 1:01:05Exhibit 267
- 1:01:08purports to be
- 1:01:10a December 23rd, 2014 email from to
- 1:01:13Elizabeth Holmes with copy to Subject
- 1:01:15line is Re: Follow-up to our call
- 1:01:18with starting days number BDT SEC
- 1:01:22_
- 1:01:22PST 0005074.
- 1:01:26Have you seen exhibit 267 before?
- 1:01:30Um, I don't recognize it, but I don't
- 1:01:32have reason to doubt the document.
- 1:01:34And was he also a member of the DDT
- 1:01:35team?
- 1:01:36I think so.
- 1:01:39So, if you look
- 1:01:41um
- 1:01:43on the bottom of exhibit 2675074,
- 1:01:48there is an email from you on December
- 1:01:5023rd, 2014.
- 1:01:53Uh, did you send that email on or about
- 1:01:55December 23rd, 2014?
- 1:01:59Again, I don't remember it, but I don't
- 1:02:00have reason to doubt the document.
- 1:02:02Okay. And so, you're sending an email to
- 1:02:05um
- 1:02:07uh, it looks like
- 1:02:09And here you you note in your email, see
- 1:02:131 2 3, the fourth paragraph down, you
- 1:02:15say, "With respect to the investment
- 1:02:17memo, our team had a mini heart attack
- 1:02:19seeing our complete strategy, future
- 1:02:21plans, unannounced deals, and profit
- 1:02:23margins delineated in a single document
- 1:02:25like that, especially without any
- 1:02:27encryption of the document. Do you see
- 1:02:29that?
- 1:02:30Yes.
- 1:02:31Does this refresh your recollection that
- 1:02:33you reviewed the memo
- 1:02:34at the time?
- 1:02:35No.
- 1:02:37How would you know that the memo
- 1:02:39included all of these things like
- 1:02:41Theranos' complete strategy, future
- 1:02:42plans, unannounced deals, and profit
- 1:02:44margin uh, margins unless you reviewed
- 1:02:46it?
- 1:02:47Looks like our team reviewed it. I don't
- 1:02:49know who.
- 1:02:52Who on your team would have reviewed the
- 1:02:54memo?
- 1:02:55I don't know.
- 1:02:56Who else received the memo besides you
- 1:02:58and Mr. Balwani?
- 1:02:59I don't know.
- 1:03:01If you look a little further down in the
- 1:03:02the that same paragraph, it
- 1:03:04says, "Let me know if the if the intent
- 1:03:07is for this to go only to persons who
- 1:03:09have committed to participate
- 1:03:12to a co-investment to a broader group.
- 1:03:15Semicolon, I'd like to get a sense of
- 1:03:16what the purpose of the document is at
- 1:03:18this stage, and we can then send back
- 1:03:20our thoughts and edits based on what
- 1:03:22we're you're trying to do uh with it at
- 1:03:24this point.
- 1:03:26Do you see that?
- 1:03:26Yes.
- 1:03:27What what were you asking there?
- 1:03:30So, now that you're reading it now, I
- 1:03:32assume I'm saying what what is the
- 1:03:33purpose of the document, and then we'll
- 1:03:35edit it based on the intended audience.
- 1:03:38Did you Did you not understand the
- 1:03:39purpose of the document be-
- 1:03:41before asking him?
- 1:03:43I mean, I assume I did not, given that
- 1:03:46I'm asking here.
- 1:03:50So, going back to exhibit 266,
- 1:03:55I want to turn to the attachment to the
- 1:03:57email.
- 1:03:58Yes.
- 1:03:59And look at the page number ending with
- 1:04:02page number ending 1172.
- 1:04:12Oh, actually first, could you um
- 1:04:14actually start on
- 1:04:161169.
- 1:04:24You'll see this is the cover page of the
- 1:04:26memorandum.
- 1:04:31And it's titled project test. Do you see
- 1:04:33that?
- 1:04:34Yes.
- 1:04:35Did you understand in your discussions
- 1:04:36with BDT Capital that they were using
- 1:04:38test uh as a code name for Theranos?
- 1:04:42I don't remember that, um but it looks
- 1:04:45like it was.
- 1:04:46Okay. Why don't you turn to 1172?
- 1:04:55So, I want to focus on
- 1:04:57uh the portion of this page under
- 1:04:59compelling strategic plan.
- 1:05:02You'll see on the third paragraph down,
- 1:05:04it says,
- 1:05:06"In conjunction with its execution of
- 1:05:07its seven-pronged strategic plan, the
- 1:05:10company is currently negotiating the
- 1:05:11terms of the contract with the US
- 1:05:13government to provide testing services
- 1:05:15for Ebola within US airports and
- 1:05:18alongside the US military and aid
- 1:05:20agencies in West Africa.
- 1:05:23Did you tell you this?
- 1:05:27I don't remember a specific
- 1:05:30um conversation to that effect.
- 1:05:31Do you remember a general conversation
- 1:05:33to that effect?
- 1:05:35I I don't remember general conversations
- 1:05:37to that effect. I know at the time we
- 1:05:39were devoting a lot of resources to the
- 1:05:41submission of an emergency use
- 1:05:43authorization for Ebola and were hopeful
- 1:05:46that we would be able to engage in
- 1:05:47contracting opportunities.
- 1:05:51So, you remember
- 1:05:53that you were and you were hopeful about
- 1:05:56engaging in contract opportunities. Were
- 1:05:58you
- 1:06:00Were you negotiating the terms of a
- 1:06:01contract with the US government at that
- 1:06:03time with respect to Ebola?
- 1:06:07Not that I can recall.
- 1:06:08So, would the statement be true as of
- 1:06:11late 2014?
- 1:06:15I don't think so, but I I can't remember
- 1:06:17exactly who we were engaging with on
- 1:06:20Ebola contracting.
- 1:06:22Did
- 1:06:23Who would know the answer to that?
- 1:06:25Um
- 1:06:27I don't know.
- 1:06:28I don't know. We We need to look back at
- 1:06:30um how we were doing this at that time.
- 1:06:33I haven't thought about it for a long
- 1:06:34time.
- 1:06:36Did you hear Mr. Balwani make a
- 1:06:38statement to this effect that the the
- 1:06:39company is currently negotiating the
- 1:06:41terms of a contract with the US
- 1:06:42government with respect to Ebola?
- 1:06:46I I can't remember any discussions to
- 1:06:47that effect.
- 1:06:50If you turn to the next page, which is
- 1:06:521173
- 1:06:56under technology and hardware, the
- 1:06:58second paragraph down
- 1:07:00the memorandum says, "Samples for all
- 1:07:02tests are run on one proprietary
- 1:07:04diagnostic machine, an unprecedented
- 1:07:07capability in testing, and a significant
- 1:07:09technological competitive advantage
- 1:07:11versus peers. Did you tell me that?
- 1:07:17Um to the extent we were discussing the
- 1:07:18mini lab, um yes.
- 1:07:21That's what the mini lab is architected
- 1:07:22to do.
- 1:07:24It says all tests are run on one
- 1:07:27Is this an aspirational statement then
- 1:07:29in your mind or
- 1:07:31Um yes, it's a description of the design
- 1:07:34of the mini lab. We
- 1:07:36Yes.
- 1:07:41Did you tell the capital that Theranos
- 1:07:44was not actually using
- 1:07:46its proprietary diagnostic machine to
- 1:07:48perform patient tests?
- 1:07:51Or all patient tests rather, that it was
- 1:07:53only performed that it was it was only
- 1:07:55being used perform a small subset of the
- 1:07:57tests?
- 1:07:58I don't think we had discussions about
- 1:08:00what it was being used to do in the in
- 1:08:02the clinical lab.
- 1:08:04Why not?
- 1:08:06Because the bulk of our focus was on
- 1:08:08phase two of our model, and getting the
- 1:08:10machine out and distributed.
- 1:08:12The capital wasn't interested in what
- 1:08:13Theranos was doing at the time?
- 1:08:16I I don't know what they were interested
- 1:08:18in. Did they ever ask you questions
- 1:08:19about what Theranos was doing at the
- 1:08:21time?
- 1:08:22I again I can't remember the specifics
- 1:08:24of the conversations with them.
- 1:08:28Did you hear Mr. Balwani make a
- 1:08:29statement like this to you that samples
- 1:08:31of all tests are run on one proprietary
- 1:08:33diagnostic machine?
- 1:08:36Again, I can't remember the specifics of
- 1:08:38conversations with
- 1:08:41Return to 1174.
- 1:08:51Under test accuracy, second paragraph
- 1:08:53down, it says a validation study
- 1:08:56published by Johns Hopkins in 2010
- 1:08:59concluded that the the technology is
- 1:09:01novel and sound. It can accurately run a
- 1:09:03wide range of routine and special assays
- 1:09:06and that no major weaknesses were
- 1:09:08identified. Did you tell that there was
- 1:09:10a validation study that was published by
- 1:09:12Johns Hopkins in 2010 that concluded
- 1:09:14that?
- 1:09:17I don't think we told them. My memory is
- 1:09:19they actually got access to the the
- 1:09:22Johns Hopkins document in and of itself.
- 1:09:25Your memory is that they got access to
- 1:09:27the Johns Hopkins document. Are you
- 1:09:28talking about the April 2010 document
- 1:09:31document?
- 1:09:32I I think so. Yeah.
- 1:09:33How did they gain access to that
- 1:09:35document?
- 1:09:36I'm not sure if we gave it to them or
- 1:09:38somebody else gave it to them. I'm not
- 1:09:39sure.
- 1:09:41Did you ever describe the
- 1:09:45the April 2010 document from Johns
- 1:09:47Hopkins as a validation study?
- 1:09:51I don't remember specific conversations
- 1:09:53to that effect.
- 1:09:55Other than the Johns Hopkins report, do
- 1:09:57you do you remember anything else that
- 1:09:58was provided to
- 1:10:01I don't. I I know we were actively
- 1:10:03engaged with them over a period of
- 1:10:05months on a lot of different aspects of
- 1:10:06our business, so I'm sure they had
- 1:10:08access to a lot of content.
- 1:10:11Did you hear Mr. Balwani make the
- 1:10:13statement to you that there was a
- 1:10:15validation study that was published by
- 1:10:16Johns Hopkins in 2010?
- 1:10:19Not that I can remember.
- 1:10:22On that same page under select clinical
- 1:10:24correlations,
- 1:10:26the memorandum states
- 1:10:28The company has validated all of its
- 1:10:29tests versus traditional laboratory and
- 1:10:32reference methods to demonstrate their
- 1:10:34accuracy.
- 1:10:36Did you tell this?
- 1:10:38I don't know.
- 1:10:41Was this true in
- 1:10:43December 2014?
- 1:10:47I might Again, I haven't read the
- 1:10:49document, so I'm not sure specifically
- 1:10:51whether this is referring to product
- 1:10:52development or
- 1:10:54the clinical lab. I'm we we thought had
- 1:10:57done this
- 1:10:58I'm both in tests we developed on the
- 1:11:01product development side as well as
- 1:11:03tests we had validated as LDTs in the
- 1:11:06clinical lab.
- 1:11:07Did you make clear to B at this time in
- 1:11:09December or late 2014 that the clinical
- 1:11:13the clinical data that you were showing
- 1:11:15them pertained to
- 1:11:17uh
- 1:11:18data that was generated in the R&D lab
- 1:11:21and not in the clinical lab that was
- 1:11:24performing to patient testing?
- 1:11:26I I don't know if we showed them data
- 1:11:28from the lab the LDTs or R&D data.
- 1:11:31Certainly to the extent that we showed
- 1:11:34R&D data, my memory is we generally
- 1:11:35would describe it as product development
- 1:11:38data and all the tests we created.
- 1:11:45Turning to
- 1:11:47page 1175
- 1:11:50under manufacturing
- 1:11:53the memorandum states "Theranos
- 1:11:55currently manufactures 100% of its
- 1:11:57diagnostic machines and associated
- 1:11:59consumables in a single plant in Newark,
- 1:12:02California." Do you Did you tell B
- 1:12:04Capital that Theranos currently
- 1:12:06manufactured 100% of its diagnostic
- 1:12:09machines in Newark, California
- 1:12:12as of December 2014?
- 1:12:15To the extent it's referring to
- 1:12:17the mini lab and all of the components
- 1:12:19in the mini lab.
- 1:12:22What
- 1:12:23You did You did tell B Capital that?
- 1:12:25I I don't know that I personally said
- 1:12:27that, but
- 1:12:28that was something that Theranos was
- 1:12:29very proud of that every component of
- 1:12:31mini lab was manufactured in
- 1:12:34this Newark facility.
- 1:12:36The mini lab wasn't 100% of Theranos'
- 1:12:39diagnostic machines at the time, was it?
- 1:12:43No. Um just 100% of the mini lab was
- 1:12:47manufactured in the Newark facility.
- 1:12:50So was the statement true as of December
- 1:12:522014?
- 1:12:55Um only with respect to the mini lab.
- 1:13:00The statement isn't qualified with
- 1:13:02respect to mini lab, is it?
- 1:13:05No, again, I I I don't think I've ever
- 1:13:08read this whole document, so I'm not
- 1:13:09sure
- 1:13:11if this is talking about the clinical
- 1:13:13lab or the technology we were working to
- 1:13:14develop.
- 1:13:19Did you ever hear Mr. Balwani make this
- 1:13:21statement to Capital?
- 1:13:23Not that I can remember.
- 1:13:26Uh
- 1:13:27the third paragraph down, it says,
- 1:13:29"Unlike other sector participants, Test
- 1:13:32operates a vertically integrated
- 1:13:34manufacturing model.
- 1:13:36The company receives raw materials,
- 1:13:39e.g., plastic, aluminum, etc., and
- 1:13:41constructs each and every component of
- 1:13:43the finished products,
- 1:13:44diagnostic machines, and associated
- 1:13:46consumables." Did you tell V this?
- 1:13:49Again, I I don't remember specific
- 1:13:51conversations with
- 1:13:53Did you hear Mr. Balwani make this
- 1:13:55statement to
- 1:13:55Not that I can remember.
- 1:13:57Was the statement true as of December
- 1:13:582014?
- 1:14:00With respect to our mini lab.
- 1:14:03Is the statement in any way qualified
- 1:14:05with respect to the mini lab?
- 1:14:08Again, I I haven't read this document,
- 1:14:10so I don't know what the pretext to this
- 1:14:12is.
- 1:14:13This section um just talks about uh
- 1:14:18diagnostic machines.
- 1:14:21And Theranos was using other diagnostic
- 1:14:23machines besides the mini lab in
- 1:14:25December 2014, correct?
- 1:14:27In its clinical lab, yes.
- 1:14:34If you turn to 1178
- 1:14:37and 1179,
- 1:14:40starting on page 1178, there's a section
- 1:14:44called Walgreens. Do you see that
- 1:14:46halfway down the page?
- 1:14:47Yes.
- 1:14:48Okay, if you flip over to 1179 very top.
- 1:14:55The very top of the page there's a
- 1:14:57sentence that starts the contract does
- 1:14:59not limit.
- 1:15:02So, the memo is talking about Walgreens
- 1:15:04and it says that the contract does not
- 1:15:06limit or restrict tests from opening
- 1:15:08additional locations if the company
- 1:15:10chooses to do so.
- 1:15:12Did you tell Capital that?
- 1:15:14In December? Uh around December 2014.
- 1:15:18I don't think so. My memory is we gave
- 1:15:19them access to the Walgreens agreement
- 1:15:21and they reviewed it directly.
- 1:15:23Did you hear Mr. Balwani make this
- 1:15:25statement to the Capital?
- 1:15:26No, again I I don't remember any
- 1:15:27specifics of the conversations.
- 1:15:29Okay.
- 1:15:30Was the statement true as of December
- 1:15:322014?
- 1:15:36Do you mind if I read the paragraph?
- 1:15:38Sure.
- 1:16:08I don't know.
- 1:16:11Was it true that
- 1:16:15the contract
- 1:16:16the Walgreens contract didn't doesn't
- 1:16:20restrict Theranos from opening
- 1:16:21additional locations if Theranos chose
- 1:16:23to do so?
- 1:16:27I don't know.
- 1:16:29Wasn't it true that Walgreens and
- 1:16:30Theranos had to work together to plan
- 1:16:32out additional locations together?
- 1:16:36I I I yes, I remember that in certain
- 1:16:38versions of the contract. I'm not
- 1:16:41sure what this is referring to.
- 1:16:45So, if you look down another
- 1:16:49two paragraphs from there,
- 1:16:51the memorandum states, "As part of the
- 1:16:53agreement" and this is talking about the
- 1:16:55Walgreens agreement again, "the two
- 1:16:57companies will partner together to make
- 1:16:59Test the largest clinical laboratory in
- 1:17:02the US. This development is on target
- 1:17:04and the two companies anticipate
- 1:17:06achieving this milestone by the end of
- 1:17:082016."
- 1:17:09Did you tell Capital all that in late
- 1:17:112014?
- 1:17:14Um I don't think so.
- 1:17:17Did you hear Mr. Balwani make this
- 1:17:18statement to Capital?
- 1:17:19I I can't remember the specifics of
- 1:17:21conversations.
- 1:17:23Was the statement true as of December
- 1:17:252014?
- 1:17:26I don't know.
- 1:17:30Do you ever recall a time in which uh
- 1:17:31Walgreens
- 1:17:33stated it was going to make Theranos the
- 1:17:35largest clinical laboratory in the US?
- 1:17:40Um
- 1:17:41certainly
- 1:17:43the the prior
- 1:17:46um
- 1:17:48Walgreens management team had that
- 1:17:50vision. I don't remember specific
- 1:17:51conversations uh to that effect.
- 1:17:55So, the vision would be the sort of the
- 1:17:57pre-Boots leadership?
- 1:17:58Yes.
- 1:18:01So, if you look down another paragraph
- 1:18:04under that uh in the middle of the next
- 1:18:06paragraph it says,
- 1:18:08"In 2015, the company plans to
- 1:18:10dramatically expand its wellness center
- 1:18:13penetration to several hundred stores
- 1:18:15across multiple states."
- 1:18:18Did you tell Capital
- 1:18:19that
- 1:18:23No, I don't think so.
- 1:18:24Did you hear Mr. Balwani make that
- 1:18:26statement to Capital?
- 1:18:28Um I I can't remember any of the
- 1:18:29specifics of the conversations.
- 1:18:31Was that statement true as of December
- 1:18:332014?
- 1:18:36Um I again, my read on this, sitting
- 1:18:39here now, is that this was the
- 1:18:41conclusions they drew from reading the
- 1:18:42contract themselves.
- 1:18:45But you don't have any recollection that
- 1:18:47that's the basis for the statement here.
- 1:18:49I I don't. I just remember giving them
- 1:18:51access to the agreement.
- 1:18:53Okay, so we know we talked about the the
- 1:18:54agreement and then the Johns Hopkins
- 1:18:56report. Do you remember giving them
- 1:18:57access to any other information?
- 1:19:01Um
- 1:19:03I'm just thinking.
- 1:19:05Um
- 1:19:11I I don't know specifically. I I
- 1:19:13generally remember that because we had
- 1:19:15met them in the context of wanting them
- 1:19:17to advise us that we gave them broad
- 1:19:19access to a lot of content internally. I
- 1:19:22I don't I can't sit here and remember
- 1:19:23another specific document.
- 1:19:27So if you turn the page to 1180.
- 1:19:31About a third down the page, there's a
- 1:19:33section on Safeway. Do you see that?
- 1:19:35Mhm.
- 1:19:36The second paragraph starts, "The
- 1:19:37company projects to launch wellness
- 1:19:39centers within Safeway stores in 2015
- 1:19:42beginning in California." Did you tell
- 1:19:44Le Capital that?
- 1:19:48I don't think so.
- 1:19:50Did Mr. Balwani
- 1:19:51tell Le Capital that?
- 1:19:53I don't know.
- 1:19:55Was that statement true as of December
- 1:19:562014?
- 1:19:58I don't know.
- 1:20:02Going on to
- 1:20:04page with Bates numbering 1183.
- 1:20:10You'll see there is a table here in the
- 1:20:12middle of the page that's titled company
- 1:20:14projections. Do you see that?
- 1:20:16Yes.
- 1:20:19And this shows that Theranos is earning
- 1:20:25uh $8 million from physicians' offices
- 1:20:29and uh $43 million from hospital courier
- 1:20:33services in
- 1:20:35the fourth quarter of 2014. Do you see
- 1:20:37that?
- 1:20:38I do.
- 1:20:39Did you provide these projections to be
- 1:20:42No.
- 1:20:44Did Mr. Balwani provide these
- 1:20:45projections to you?
- 1:20:46I don't know.
- 1:20:48Were these projections reasonable in
- 1:20:50December 2014 that Theranos was set to
- 1:20:54make $8 million in revenue from
- 1:20:56physicians' offices and $43 million
- 1:20:58from hospitals uh,
- 1:21:01through couriering uh, samples?
- 1:21:03I don't think so.
- 1:21:05Why not?
- 1:21:06I I don't think we um,
- 1:21:09deployed the retail locations to do this
- 1:21:11in
- 1:21:122014.
- 1:21:16Did Theranos end up earning any revenues
- 1:21:19from these two sectors in fourth quarter
- 1:21:212014?
- 1:21:23I don't know.
- 1:21:27You'll also see that
- 1:21:31on the same page on the company
- 1:21:33projections
- 1:21:35page
- 1:21:37in that same table we were looking at
- 1:21:38under pharmaceutical services
- 1:21:41there's a projection of $8 million
- 1:21:43for pharmaceutical services in uh,
- 1:21:46fourth quarter of 2014 for a total of
- 1:21:49$40 million projected revenues in
- 1:21:52uh, 2014 for the year. See that?
- 1:21:55Mhm.
- 1:21:56Did you tell Capital that Theranos was
- 1:21:58on the road to achieving $40 million
- 1:22:02uh, in revenues from the pharmaceutical
- 1:22:04services?
- 1:22:05I don't think so.
- 1:22:06Did you hear Mr. Balwani
- 1:22:09make that statement to
- 1:22:10Uh, again, I I can't remember any of the
- 1:22:12specifics of the conversations I had.
- 1:22:15So, if you look at those two numbers, it
- 1:22:18would appear that Theranos would have
- 1:22:20generated about $32 million
- 1:22:23in revenues from pharmaceutical services
- 1:22:25for the rest of the year, uh, first
- 1:22:27quarter to third quarter of 2014. Do you
- 1:22:29see that?
- 1:22:31I do.
- 1:22:33Had Theranos
- 1:22:35um and generated $32 million from
- 1:22:38pharmaceutical services
- 1:22:40in first quarter to third quarter 2014?
- 1:22:44I don't think so.
- 1:22:48So, if you look on the bottom of the
- 1:22:49page
- 1:22:51under retail pharmacies
- 1:22:53the memorandum states Walgreens
- 1:22:55locations
- 1:22:57test currently has 41 wellness centers
- 1:22:59in Walgreens stores, 40 in Arizona, one
- 1:23:02in Palo Alto, California, and plans to
- 1:23:05open wellness centers in 900 total
- 1:23:07Walgreens pharmacies by year end 2015.
- 1:23:10Did you tell Capital this?
- 1:23:13I don't think so.
- 1:23:15Did you hear Mr. Balwani make this
- 1:23:16statement to Capital?
- 1:23:18Again, I can't remember any specifics of
- 1:23:20the conversations with
- 1:23:22Was this a true statement that Theranos
- 1:23:24was planning to open wellness centers in
- 1:23:25900 total Walgreens pharmacies by year
- 1:23:28end 2015?
- 1:23:32I don't know.
- 1:23:38If you turn the page to 1184
- 1:23:42under physicians offices
- 1:23:46second bullet point down, it says
- 1:23:48locations. The company is currently in
- 1:23:50101 physician offices and plans to be in
- 1:23:53approximately 700 offices by year end
- 1:23:552015.
- 1:23:57Did you tell Capital this?
- 1:23:59No.
- 1:24:00Did you hear Mr. Balwani make this
- 1:24:01statement to Capital?
- 1:24:02I don't think so.
- 1:24:03Was the statement true as of December
- 1:24:062014?
- 1:24:10I don't know. I think
- 1:24:12if we were doing physician pickup, it
- 1:24:14would have been reflective of that. I
- 1:24:15don't know when we were doing that.
- 1:24:17Was Theranos currently at that time in
- 1:24:20December 2014 in 101 physician's
- 1:24:23offices.
- 1:24:24I don't know.
- 1:24:27Was it ever?
- 1:24:29We were picking up samples from
- 1:24:31physician offices. I don't know how many
- 1:24:32physician offices we were picking up
- 1:24:34from.
- 1:24:37If you
- 1:24:38Uh turn to the next page, 1185.
- 1:24:41Under pharmaceutical services, the first
- 1:24:43bullet point says cartridges,
- 1:24:45Theranos currently runs 3,000 samples
- 1:24:48per month, 100 per day. Given current
- 1:24:51contracts, it expects that's this number
- 1:24:53to increase to 5,000 in the second half
- 1:24:55of 2015.
- 1:24:57Did you tell Capital
- 1:24:59that Theranos was currently running
- 1:25:013,000 samples from per month uh
- 1:25:05under pharmaceutical services contracts?
- 1:25:08No.
- 1:25:09Did you hear Mr. Balwani make this
- 1:25:11statement to Capital?
- 1:25:12Not that I can remember.
- 1:25:13Was the statement true as of December
- 1:25:152015?
- 1:25:16I'm sorry.
- 1:25:17Was this Was this accurate in December
- 1:25:192014?
- 1:25:22Um
- 1:25:25No, I don't I don't think so.
- 1:25:37Did you ever tell the Capital that given
- 1:25:39current contracts in pharmaceutical
- 1:25:41services that Theranos expected the
- 1:25:44number of samples run each month to
- 1:25:46increase to 5,000 in the second half of
- 1:25:492015?
- 1:25:50I don't think so.
- 1:25:52Did you ever hear uh Mr. Balwani make
- 1:25:54that statement to the Capital?
- 1:25:56Not that I can remember.
- 1:25:58Was the statement true as of December
- 1:26:002014?
- 1:26:01I don't know.
- 1:26:09You mentioned earlier that there were
- 1:26:12others on your team who might have
- 1:26:13reviewed the the memorandum and told you
- 1:26:15that it included complete uh
- 1:26:18notes about Theranos' complete strategy,
- 1:26:21future plans, unannounced deals, and
- 1:26:22profit margins. Do you remember that
- 1:26:24testimony?
- 1:26:26Uh just that I was inferring that from
- 1:26:27the email you showed me.
- 1:26:30So, you don't know whether somebody
- 1:26:31might have told you that?
- 1:26:33I again I don't remember sending this
- 1:26:35email and just looking at the language
- 1:26:37in it now and the fact that I said our
- 1:26:39team as opposed to I uh
- 1:26:43likely means that.
- 1:26:45Did anyone raise any issues with respect
- 1:26:47to the accuracy of the statements made
- 1:26:49in this memorandum to you
- 1:26:51from your team?
- 1:26:53I I honestly don't know that we read the
- 1:26:55memoranda
- 1:26:57in detail. It looks like some people
- 1:26:59looked at it, but I don't remember ever
- 1:27:01reading it.
- 1:27:04It We we we spoke before about you
- 1:27:06having a lot of access to information at
- 1:27:07Theranos, right?
- 1:27:08Yeah.
- 1:27:09And uh at this time they were they'd
- 1:27:11been working with the company for some
- 1:27:12time. Is that fair?
- 1:27:14Yes.
- 1:27:15Uh a few months.
- 1:27:16The
- 1:27:17in that in those few months you met with
- 1:27:18Balwani times. Is that fair?
- 1:27:20Yes.
- 1:27:20And with his associates several times.
- 1:27:23I I think so, yes.
- 1:27:24And it was your understanding Mr.
- 1:27:25Balwani did the same?
- 1:27:27Yes.
- 1:27:27Uh it it it does it concern you at all
- 1:27:30that this is the impression they formed
- 1:27:31on the company
- 1:27:33given the level of interaction they had
- 1:27:36by December 2014?
- 1:27:38I
- 1:27:39I'm a little bit confused by it. I'm I'm
- 1:27:41not quite sure
- 1:27:44where it's coming from or if it was just
- 1:27:47intended to be a sales piece that we
- 1:27:49were to edit. I'm I'm not I'm not sure.
- 1:27:54Certainly I
- 1:27:55I
- 1:27:56don't think we conveyed some of the
- 1:27:58things that were in it.
- 1:28:01Did it concern you that they were
- 1:28:03intending to send that memorandum to
- 1:28:05co-investors even though it included
- 1:28:07some inaccurate statements?
- 1:28:10Again, I don't know that I read it at
- 1:28:11the time. Um we certainly would have
- 1:28:14wanted to make sure it was accurate if
- 1:28:15it were going to have gone out.
- 1:28:18Why didn't you review it and and make
- 1:28:20changes and edits to it considering that
- 1:28:22they asked you to do that?
- 1:28:24I think at this time we were
- 1:28:26um
- 1:28:28beginning to think that we were not
- 1:28:29going to be doing a deal with so we
- 1:28:30weren't paying a lot of attention to it.
- 1:28:32Did you tell them at that time that you
- 1:28:34weren't going to be doing a deal with
- 1:28:35them?
- 1:28:36I think a couple weeks later or a week
- 1:28:38or so later.
- 1:28:40You you continued to meet with them in
- 1:28:41late December 2014 time period, right?
- 1:28:43I think so, yes.
- 1:28:44Did they ask you again for your feedback
- 1:28:46on this document?
- 1:28:47I don't know.
- 1:28:48Uh did anyone from
- 1:28:50I don't know.
- 1:28:54Did you ever tell PFM in early 2014 that
- 1:28:58Theranos had 300 machines that were
- 1:29:00running in Theranos' labs?
- 1:29:05Uh not that I can remember.
- 1:29:06Did you hear Sunny Balwani make this
- 1:29:08statement to PFM?
- 1:29:10Not that I can remember.
- 1:29:15Did you ever tell PFM in early 2014 that
- 1:29:18Theranos had the capability to
- 1:29:19manufacture 200 mini labs?
- 1:29:22Not that I can remember.
- 1:29:23Did you hear Sunny Balwani make this
- 1:29:25statement to PFM?
- 1:29:28Uh again, I can't remember specifics of
- 1:29:30the conversation with PFM.
- 1:29:31Was that statement true as of January
- 1:29:332014?
- 1:29:35I don't know.
- 1:29:42Did you ever tell PFM that Theranos had
- 1:29:45a road map to 1,300 assays?
- 1:29:49I don't know.
- 1:29:50Did you hear Sunny Balwani make that
- 1:29:51statement to PFM?
- 1:29:54Not that I can remember.
- 1:29:55Would this statement have been true as
- 1:29:57of January 2014?
- 1:30:01In a product development sense, yes.
- 1:30:06Did you ever tell PFM in January 2014
- 1:30:10that Theranos had developed almost all
- 1:30:12of the 1,300 assays and had launched
- 1:30:15some of the 1,300 assays?
- 1:30:19I don't remember specific discussions to
- 1:30:21that effect.
- 1:30:22Did you hear Mr. Balwani ever make that
- 1:30:24statement to PFM?
- 1:30:26Not that I can remember.
- 1:30:27Was that statement true as of January
- 1:30:282014?
- 1:30:29It's actually a compound compound
- 1:30:31statement. There's multiple quite
- 1:30:33multiple statements there.
- 1:30:34Sure, we can go through them one by one.
- 1:30:36So, did you ever tell PFM that Theranos
- 1:30:38developed 1,300 assays?
- 1:30:42No.
- 1:30:43Did you ever hear Mr. Balwani make that
- 1:30:44statement to PFM?
- 1:30:46Not that I can remember.
- 1:30:47Was that statement true as of January
- 1:30:482014?
- 1:30:50No.
- 1:30:54Did you ever tell PFM that
- 1:30:59Theranos can put
- 1:31:04Let's write that.
- 1:31:10The Duran partners was a seed two
- 1:31:11investor, correct?
- 1:31:12Yes.
- 1:31:14And and Greg Penner was the member of
- 1:31:16the Walton family that was considering
- 1:31:18an investment in Theranos on behalf of
- 1:31:20the Duran partners?
- 1:31:22I think Greg and Rob both, yes.
- 1:31:24Greg and Rob both, yeah. You were in
- 1:31:26discussions with both Mr. Penner and Mr.
- 1:31:28Walton in the fall of 2014 to invest in
- 1:31:32Theranos?
- 1:31:32Yes.
- 1:31:34Did you ever tell Mr. Penner that
- 1:31:37Theranos could execute just with the
- 1:31:39cash that it had at the time and the
- 1:31:42cash flow that it had achieved through
- 1:31:43its contracts?
- 1:31:46In the fall of 2014? Yes.
- 1:31:49Um, I don't know.
- 1:31:51Did you ever hear Mr. Balwani make that
- 1:31:53statement?
- 1:31:55I don't know.
- 1:31:56Would that have been true in
- 1:31:59late 2014?
- 1:32:02Um, I don't know.
- 1:32:28Did you ever tell Capital
- 1:32:30in September of 2014
- 1:32:33that Theranos' goal was to be in 800
- 1:32:35stores by the end of 2015?
- 1:32:38I don't know. Did you ever hear Mr.
- 1:32:40Balwani make that statement?
- 1:32:43Not that I can remember.
- 1:32:45Did you ever tell Capital that Theranos'
- 1:32:48machines cost 35 to 40,000 dollars
- 1:32:52versus a million dollars for Theranos'
- 1:32:55competitors?
- 1:32:58Not that I can remember. Did you ever
- 1:32:59hear Mr. Balwani make that statement to
- 1:33:01Capital? I don't know.
- 1:33:03Was that statement true that Theranos'
- 1:33:05machines cost 35 to 40,000 dollars?
- 1:33:10That's That's in the range of the what
- 1:33:12the cost of goods of the mini lab likely
- 1:33:14was at that time.
- 1:33:16So, that Sorry. Go ahead.
- 1:33:17What do you mean by cost of goods?
- 1:33:19Um, the
- 1:33:21the cost to make a a mini lab.
- 1:33:24Uh, just the components or the labor and
- 1:33:28I I believe all of the above that fully
- 1:33:30loaded cost of goods.
- 1:33:33Did you ever tell
- 1:33:35Capital that
- 1:33:37all of Theranos' devices work on one
- 1:33:40box,
- 1:33:41um,
- 1:33:42which is a significant advantage versus
- 1:33:44Theranos' competitors?
- 1:33:46I'm not sure I understand the question.
- 1:33:48All of the devices?
- 1:33:50Maybe it's all of their tests. Did you
- 1:33:51ever tell Capital that all of your tests
- 1:33:53work on one box?
- 1:33:55Which is different from your
- 1:33:56competitors.
- 1:33:57I don't remember saying that, but that's
- 1:33:59what the mini lab is designed to do.
- 1:34:03Did you ever hear Mr. Balwani make that
- 1:34:05statement to Capital?
- 1:34:06I don't know.
- 1:34:12Did you ever tell Capital that Theranos
- 1:34:14solves a fundamental problem for the
- 1:34:16military?
- 1:34:18Because Theranos can run tests quickly
- 1:34:20on one portable machine where no one
- 1:34:22else can.
- 1:34:24I don't know.
- 1:34:25If he said that.
- 1:34:26Mr. Did you ever hear Mr. Balwani make
- 1:34:28that statement?
- 1:34:29I don't know.
- 1:34:31Did you ever tell Capital that all of
- 1:34:34Theranos' tests can be run on one
- 1:34:35machine with one disposable cartridge?
- 1:34:39Again, I I don't remember the specifics
- 1:34:41of conversations, but that's what mini
- 1:34:43lab is designed to do.
- 1:34:45Did you ever hear Mr. Balwani make that
- 1:34:47statement?
- 1:34:48I don't know.
- 1:34:50So, of course that wouldn't have applied
- 1:34:51to the tests that Theranos was
- 1:34:53conducting in patient testing, correct?
- 1:34:57Repeat that question again. Sorry.
- 1:34:59What do you mean?
- 1:35:00So, it's not true that all of all of
- 1:35:02Theranos' tests were being performed on
- 1:35:04the mini lab, correct?
- 1:35:06Correct.
- 1:35:07That a majority of the tests were
- 1:35:08actually performed on commercially
- 1:35:09available machines, correct?
- 1:35:11Absolutely.
- 1:35:26What is Fremont Group?
- 1:35:29It's a fund that manages mostly the
- 1:35:32Bechtel family money.
- 1:35:34Were you in discussions in late 2014
- 1:35:37about a possible investment in Theranos
- 1:35:39from Fremont Group?
- 1:35:41Yes.
- 1:35:42Who were your discussions with?
- 1:35:44Um primarily
- 1:35:45Was there anyone else who was involved
- 1:35:47in those discussions?
- 1:35:48Um there was
- 1:35:51and I I don't remember the names of the
- 1:35:52principals.
- 1:35:53Was one of them?
- 1:35:54I think so.
- 1:35:58Do you remember the other?
- 1:36:00I don't know.
- 1:36:02Did you give Fremont Group a copy of
- 1:36:04Theranos' financial model which showed
- 1:36:06projections?
- 1:36:08I did not. I I don't know if
- 1:36:12I did not. I don't know if anyone else
- 1:36:14at Theranos did.
- 1:36:15Did Sunny Balwani provide financial
- 1:36:18projections to Fremont Group?
- 1:36:20I don't know.
- 1:36:23Did you tell Fremont Group in late 2014
- 1:36:26that the financial numbers
- 1:36:29that Theranos' financial numbers were
- 1:36:31based on no new contracts?
- 1:36:35I don't think No.
- 1:36:37Did you hear Mr. Balwani make the
- 1:36:38statement to Fremont Group in late 2014?
- 1:36:41Not that I can remember.
- 1:36:42Was this statement true as of late 2014?
- 1:36:47I don't know.
- 1:36:49Did you tell anyone from the Fremont
- 1:36:50Group that Theranos' assay run test time
- 1:36:53was always less than 1 hour?
- 1:36:56I don't know.
- 1:36:57Would that Do you recall Mr. Balwani
- 1:36:58saying that to anyone from the Fremont
- 1:37:00Group?
- 1:37:01Not that I can recall.
- 1:37:02Would Would that have been a true
- 1:37:03statement in October of 2014?
- 1:37:07Um, to the extent we were talking about
- 1:37:09the design of the mini lab, but not
- 1:37:12testing our clinical lab.
- 1:37:16Did you tell Fremont Group
- 1:37:19Let me start again. Did you tell Fremont
- 1:37:21Group in late 2014 that devices now cost
- 1:37:25$40,000 fully loaded?
- 1:37:29Not that I can remember.
- 1:37:30Did you hear Mr. Balwani make that
- 1:37:32statement to Fremont Group?
- 1:37:34I don't know.
- 1:37:35Was that statement true in late 2014?
- 1:37:39I don't know.
- 1:37:45Did you tell Fremont Group in late 2014
- 1:37:48that Theranos had put its TSPU on a
- 1:37:50Medevac helicopter?
- 1:37:52No.
- 1:37:54Why do you say no?
- 1:37:57Because I No, I've never said that.
- 1:37:59You never said that. Okay.
- 1:38:00Um did you hear Sunny Balwani make this
- 1:38:02statement to Fremont Group?
- 1:38:04No.
- 1:38:07Would the statement have been true in
- 1:38:09late 2014?
- 1:38:10No.
- 1:38:21Did you tell Capital in October 2014
- 1:38:25that Theranos
- 1:38:27had an auditor
- 1:38:28and that its financial statements were
- 1:38:30audited as well?
- 1:38:34Um I I don't know. I I know we were
- 1:38:37discussing a new audit with them.
- 1:38:40What do you recall about your
- 1:38:41conversations regarding the new audit?
- 1:38:44Um that we were discussing with them
- 1:38:46engaging with KPMG to get an audit done.
- 1:38:52Oh, in what context were they surprised
- 1:38:54that
- 1:38:55Theranos wasn't getting audits done?
- 1:38:58No, I believe we were talking about
- 1:39:01getting audits done on a go-forward
- 1:39:02basis.
- 1:39:05Did they ever ask to see audited
- 1:39:07financials, historical financials?
- 1:39:10I don't know.
- 1:39:12They might have. I can't remember.
- 1:39:20Did you ever tell Capital that KPMG was
- 1:39:22Theranos's current auditor
- 1:39:25in late 2014?
- 1:39:27I don't know.
- 1:39:28Did you hear Mr. Balwani make that
- 1:39:30statement to Capital?
- 1:39:32Just so I understand the question, what
- 1:39:33do you mean by current auditor?
- 1:39:35That KPMG had been hired by Theranos to
- 1:39:37act as its auditor
- 1:39:40as of late 2014.
- 1:39:42Um we may have discussed it in terms of
- 1:39:45the past years, but I know we discussed
- 1:39:47with it we didn't have
- 1:39:49um certain years audited.
- 1:39:51Did you hear Mr. Balwani make that
- 1:39:53statement to Capital that KPMG was
- 1:39:55Theranos' current auditor as of late
- 1:39:582014?
- 1:39:59I'm not quite sure what current auditor
- 1:40:01means, but no, I don't remember the
- 1:40:02specifics of conversations.
- 1:40:04Did Theranos have an auditor as of late
- 1:40:072014?
- 1:40:09Not for calendar year 2014, no.
- 1:40:13Did you ever tell any
- 1:40:14We were engaged with KPMG at that time
- 1:40:16about auditing
- 1:40:18uh recent years.
- 1:40:20Did you ever tell any
- 1:40:22with them. I'm sorry.
- 1:40:23No, I apologize.
- 1:40:24Good.
- 1:40:25Does that cover it?
- 1:40:26Yes.
- 1:40:27No, no, I didn't
- 1:40:27Sorry.
- 1:40:28I was trying to be complete.
- 1:40:29No, I appreciate it. The uh did you ever
- 1:40:31tell any prospective investors that they
- 1:40:34couldn't see Theranos' audited
- 1:40:35financials because they revealed
- 1:40:38commercially sensitive information about
- 1:40:39the company?
- 1:40:41Not that I can remember. I I believe
- 1:40:44that was a discussion about how we would
- 1:40:46share go-forward financials, but not
- 1:40:49historical ones.
- 1:40:51Uh what do you mean by that?
- 1:40:53Um we were very focused in getting
- 1:40:56audits.
- 1:40:57It had we proceeded with getting audits
- 1:40:59done at that time
- 1:41:01uh about the disclosure of those
- 1:41:03materials once they were complete
- 1:41:05uh
- 1:41:06with respect to how they handled
- 1:41:07footnotes on the Walgreens and Safeway
- 1:41:09contracts specifically.
- 1:41:11So, you were anticipating sharing
- 1:41:13audited financials with shareholders on
- 1:41:15a go-forward basis?
- 1:41:18I
- 1:41:18I'm not sure exactly. I don't remember
- 1:41:20the discussions very specifically, but I
- 1:41:22I know that was an area of focus
- 1:41:25uh when we were talking about starting
- 1:41:26to get audited financials done at that
- 1:41:28time.
- 1:41:30Did the board ever encourage you to
- 1:41:32get completed audited financials?
- 1:41:34Not that I can remember.
- 1:41:36Did you tell the board that Theranos had
- 1:41:38not completed its
- 1:41:39annual audits in sometime?
- 1:41:41Yes.
- 1:41:44Did you ever tell potential investors
- 1:41:46that Theranos couldn't share audited
- 1:41:48financials with them because it wasn't
- 1:41:50sharing audited financials with other
- 1:41:52investors?
- 1:41:55Uh we generally disclosed that we didn't
- 1:41:57have audited financials is my memory. Uh
- 1:42:00I I again, if there's a specific
- 1:42:01conversation, I could try to speak to it
- 1:42:03more specifically.
- 1:42:05Who do you recall having a conversation
- 1:42:07with about the fact that Theranos had no
- 1:42:09audited financials?
- 1:42:11I I don't recall a specific
- 1:42:12conversation. I just know we were very
- 1:42:14open about it.
- 1:42:17Did you ever tell Capital in late 2014
- 1:42:20that there were no proximity uh Sorry,
- 1:42:22let me start over again.
- 1:42:24Did you ever tell Capital in late 2014
- 1:42:26that there were no proximity limitations
- 1:42:28in the Walgreens contract, just time
- 1:42:31exclusivity?
- 1:42:33I I don't know what that means.
- 1:42:35Did you ever tell Capital that
- 1:42:38um
- 1:42:41that
- 1:42:42uh
- 1:42:43there were no geographic
- 1:42:46limitations to the roll out of Theranos
- 1:42:48services at Walgreens locations in late
- 1:42:502014?
- 1:42:52I'm sorry, just so I can answer your
- 1:42:54question. What is a geographic
- 1:42:55limitation?
- 1:42:56That there was no that the company that
- 1:42:58the two companies had not discussed any
- 1:43:00limitations as to the roll out of
- 1:43:03Theranos services in Walgreens stores in
- 1:43:062015.
- 1:43:08Sorry, Jessica, so I don't understand
- 1:43:10what you're asking.
- 1:43:12Okay, let me start over again.
- 1:43:13Yeah.
- 1:43:14Did you ever tell Capital that there
- 1:43:16were no geographical limitations to
- 1:43:18where Theranos could roll out its
- 1:43:20services in Walgreens stores?
- 1:43:24So
- 1:43:25just making sure I'm answering the
- 1:43:26question you're asking. The question is
- 1:43:29that we could roll out anywhere in the
- 1:43:31country?
- 1:43:32Yes.
- 1:43:33Um I don't remember specifically saying
- 1:43:35that.
- 1:43:36Did you ever hear Mr. Balwani making
- 1:43:37that statement to Capital?
- 1:43:40Not that I can remember.
- 1:43:42Was that true as of
- 1:43:44late 2014?
- 1:43:46Was what true?
- 1:43:47That statement.
- 1:43:48Can you say one more time cuz none of us
- 1:43:50we were all having a hard time so I want
- 1:43:52to make sure she knows
- 1:43:54what you're asking. What statement?
- 1:43:56That there were no geographic
- 1:43:57limitations to the roll out of Theranos
- 1:43:59services in Walgreens stores. Did you
- 1:44:01ever hear Mr. Balwani make that
- 1:44:03statement
- 1:44:04to Capital?
- 1:44:05Not that I can recall.
- 1:44:06Was that a true statement as of 2014?
- 1:44:10I I don't really understand it um but
- 1:44:14I mean again I know um I had access to
- 1:44:16the Walgreens agreement.
- 1:44:18And it was true that Theranos had to
- 1:44:19work with Walgreens in order to decide
- 1:44:21which additional stores to roll out
- 1:44:23Theranos services in, correct?
- 1:44:26I mean as as we've discussed today that
- 1:44:29relationship evolved so much that I
- 1:44:31don't know what the state of it was in
- 1:44:33December '14 from memory.
- 1:44:39It's true that Theranos couldn't
- 1:44:40unilaterally decide to roll out in any
- 1:44:43number of Walgreens stores without
- 1:44:45Walgreens consent, correct?
- 1:44:48Of course they had to work with us on
- 1:44:49it.
- 1:44:50Okay.
- 1:44:53And you guys you understood that in
- 1:44:54December 2014, is that correct?
- 1:44:57Yes, they're stores. They would have to
- 1:44:59be compliant with us
- 1:45:01showing up in them.
- 1:45:04Did you ever tell Capital in late 2014
- 1:45:08that you were fairly confident on
- 1:45:12hitting the 2014 financial projections?
- 1:45:16I don't think so.
- 1:45:17Did you ever hear Mr. Balwani make that
- 1:45:19statement?
- 1:45:20Not that I can remember.
- 1:45:30Did you ever tell Capital in late 2014
- 1:45:32that with respect to 2015 projections,
- 1:45:35you believe that there could be a plus
- 1:45:36or minus 30% variance due largely to
- 1:45:40risk of execution?
- 1:45:41I don't think so.
- 1:45:42Did you ever hear Mr. Balwani make that
- 1:45:44statement?
- 1:45:44Not that I can remember.
- 1:46:06You testified earlier that RDV
- 1:46:08Corporation is the DeVos family,
- 1:46:09correct?
- 1:46:11Yes.
- 1:46:12Who were your contacts at RDV
- 1:46:14Corporation?
- 1:46:16At what time?
- 1:46:18Uh around the time that they were
- 1:46:19considering to invest in Theranos.
- 1:46:22Um I believe
- 1:46:24Was it
- 1:46:25Did you understand that he was part of
- 1:46:26his team?
- 1:46:28I don't know if I knew that at that
- 1:46:30time. I met I think later.
- 1:46:33And Theranos was having discussions with
- 1:46:35RDV Corporation in uh late 2014 about
- 1:46:38possibly investing in Theranos, correct?
- 1:46:41Yes.
- 1:46:43Did you tell RDV Corporation in late
- 1:46:462014 that instead of vials of blood, one
- 1:46:50for every test needed, that Theranos
- 1:46:52required requires only a pinprick and a
- 1:46:54drop of blood to perform hundreds of
- 1:46:56tests?
- 1:46:58I don't know.
- 1:46:59Was that statement true as of late 2014?
- 1:47:02Could you perform hundreds of tests on
- 1:47:04one pin pinprick of blood?
- 1:47:07We had developed hundreds of tests to
- 1:47:10run on a pinprick of blood at that time.
- 1:47:12It from a product development
- 1:47:14standpoint.
- 1:47:15So earlier we had talked about how it
- 1:47:16was 70 tests on one pinprick of blood.
- 1:47:19So now you're saying that a hundreds of
- 1:47:21tests could be performed on one finger
- 1:47:24prick
- 1:47:25sample of blood.
- 1:47:26Jesse, you just mischaracterized
- 1:47:29one
- 1:47:30you mischaracterized the earlier
- 1:47:31testimony right now and what she just
- 1:47:33said in response to your question.
- 1:47:34They're two different questions. I mean
- 1:47:35I
- 1:47:37Elizabeth can answer but
- 1:47:38I think you should ask the question
- 1:47:39rather than suggest that she's saying
- 1:47:41one thing now versus one thing earlier.
- 1:47:43Well, can you square those two? That was
- 1:47:45what I understood that you said. So, can
- 1:47:46you square those two?
- 1:47:48Which one is accurate?
- 1:47:51So, are you assuming that only one can
- 1:47:52be? That's not what I
- 1:47:53Okay. So, if both of them are accurate,
- 1:47:55how are they both accurate?
- 1:47:56Yeah, I believe earlier today we were
- 1:47:58talking about how from a product
- 1:48:00development standpoint the
- 1:48:03the novel chemistries that we developed
- 1:48:05could work with a as low as a microliter
- 1:48:07or less of blood.
- 1:48:09And and therefore, if you you could run
- 1:48:1170 of them for example from a single
- 1:48:14sample.
- 1:48:16Additionally, by this time fall of '14,
- 1:48:20Theranos had created, developed, and had
- 1:48:23development in what we thought were
- 1:48:24validation reports for hundreds
- 1:48:28of chemistries that we had actually made
- 1:48:30the reagents for, made the chemistry
- 1:48:32for, shown that the chemistry worked on
- 1:48:34small sample volumes
- 1:48:36from a product development standpoint.
- 1:48:39So, so what your testimony is is that
- 1:48:40the
- 1:48:41the
- 1:48:42if there's a reference to hundreds off
- 1:48:44of a
- 1:48:45off of a drop of blood,
- 1:48:47it's
- 1:48:49not 100 of tests with the same drop of
- 1:48:51blood, but one drop
- 1:48:53for each of those 100 tests
- 1:48:55or or something like that.
- 1:48:56my understanding of the statement that
- 1:48:58you just
- 1:48:59made.
- 1:49:04Did you ever hear Mr. Balwani make the
- 1:49:06statement that Theranos required is only
- 1:49:08a pin prick and a drop of blood to
- 1:49:10perform hundreds of tests?
- 1:49:13I I don't know.
- 1:49:21Did you
- 1:49:22tell RDB Corporation in late 2014 that
- 1:49:26Theranos' revenue for 2015 is projected
- 1:49:29to be $990 million?
- 1:49:32I don't think so.
- 1:49:33Did you ever hear Mr. Balwani make that
- 1:49:35statement?
- 1:49:36Not that I can remember.
- 1:49:39Did you ever tell RDB Corporation that
- 1:49:43Theranos would open
- 1:49:46or or was on the path to opening 900
- 1:49:48Walgreens Theranos centers by 2015?
- 1:49:51I don't think so.
- 1:49:52Did you ever hear Mr. Balwani make that
- 1:49:55statement?
- 1:49:56Not that I can remember.
- 1:49:58Did you ever tell RDB Corporation that
- 1:50:00Theranos has no debt
- 1:50:02and has no plans to take on any debt
- 1:50:04financing?
- 1:50:05I don't think so.
- 1:50:06Did you ever hear Mr. Balwani make that
- 1:50:08statement?
- 1:50:08Not that I can remember.
- 1:50:10Was that statement true as of late 2014?
- 1:50:13I think so.
- 1:50:14Did you consider
- 1:50:16uh the Walgreens convertible note and
- 1:50:18the Safeway convertible note as debt?
- 1:50:22I I don't know.
- 1:50:24What did you consider that as?
- 1:50:27Not debt.
- 1:50:28I I'm not sure. I don't know.
- 1:50:30Was there interest that Theranos was
- 1:50:32paying on that loan those two loans?
- 1:50:36At that time I I don't know if we were
- 1:50:38thinking that that loan was going to
- 1:50:40convert into equity. I'm not sure how we
- 1:50:42were thinking about it.
- 1:50:46So, it's been a little over an hour. Can
- 1:50:47we take a break?
- 1:50:49Or are you going to be here?
- 1:50:50You know, I'm still in the middle of
- 1:50:50this document, so I only have a few more
- 1:50:52questions and then we can take a break.
- 1:50:54Okay.
- 1:50:55Apart from the end of the day.
- 1:50:57I have three more questions.
- 1:50:58Not from the totally from the end.
- 1:51:00No, no, no.
- 1:51:00For the for the day.
- 1:51:01Why don't we talk about that at the
- 1:51:02break and I think there's just a couple
- 1:51:04more questions on this kind of theme and
- 1:51:05then we can
- 1:51:07Did you ever tell RDB Corporation in
- 1:51:09late 2014 that cash you would raise from
- 1:51:12them would be used to redeem earlier
- 1:51:14investors with shorter term investment
- 1:51:16horizons.
- 1:51:17Could you read that again?
- 1:51:19Did you ever tell capital that
- 1:51:22Sorry, RDD?
- 1:51:23I'm sorry. Did you ever tell RDD
- 1:51:24corporation in late 2014 that cash you
- 1:51:28were going to raise
- 1:51:30from them and other investors would be
- 1:51:32used to redeem earlier investors with
- 1:51:34shorter term investment horizons?
- 1:51:37I don't know if I said that, but that
- 1:51:38was definitely one of the strategies for
- 1:51:41raising money from long-term family sort
- 1:51:43of controlled companies and investment
- 1:51:46entities.
- 1:51:47Did you ever hear Mr. Balwani make that
- 1:51:48statement?
- 1:51:49I don't know.
- 1:51:53Did Theranos ever redeem earlier
- 1:51:54investors with the C2 proceeds?
- 1:51:58Not in the way we had wanted to, which
- 1:52:00was
- 1:52:02sort of
- 1:52:03buy out um
- 1:52:06certain entities that we had learned did
- 1:52:09not have sort of a long-term interest in
- 1:52:10holding the shares. Um we we did a
- 1:52:12little bit of exercising the right of
- 1:52:15first refusal to make sure that shares
- 1:52:18didn't end up in secondary markets.
- 1:52:20I guess what why didn't Theranos uh sort
- 1:52:23of pursue that
- 1:52:25uh shareholder consolidation strategy
- 1:52:27more aggressively?
- 1:52:29Because shortly after we closed this
- 1:52:31round, we started dealing with the Wall
- 1:52:32Street Journal and then very shortly
- 1:52:34after that we're
- 1:52:36in
- 1:52:38sort of crisis mode trying to deal with
- 1:52:40the issues with the Journal and then
- 1:52:41regulators.
- 1:52:42Is it just general timing?
- 1:52:45Yes, we we didn't get the chance to
- 1:52:47execute on the plan we had.
- 1:52:50Did you tell RDD corporation in late
- 1:52:522014 that Theranos uses its own analyzer
- 1:52:55equipment?
- 1:52:58I I don't know if I did. I'm
- 1:53:00I'm I'm not sure.
- 1:53:01Did you ever hear Mr. Balwani make that
- 1:53:03statement?
- 1:53:04Uh again, I can't remember the specifics
- 1:53:06of these conversations. don't, I don't
- 1:53:07know.
- 1:53:09Did you ever tell RDV Corporation in
- 1:53:12late 2014 that the Theranos analyzer
- 1:53:15is a small fraction of the size of a
- 1:53:17current lab?
- 1:53:20I can't remember the specifics of the
- 1:53:22conversation, but
- 1:53:24that's reflective of mini lab.
- 1:53:27Did you ever hear Mr. Balwani make that
- 1:53:28statement to um sorry, to RDV Corp
- 1:53:30Corporation?
- 1:53:31I I don't know.
- 1:53:35Okay.
- 1:53:36Okay, we can take a break. We are off
- 1:53:37the record at 3:34.
About this transcript
This page contains the full transcript of Elizabeth Holmes SEC Deposition AUG 23, 2017 3 OF 4 redacted by ANTL Media, generated from the public captions YouTube serves with the video. The transcript has 16,073 words across 3,046 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.